<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="liv16132" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Liver Int</journal-id><journal-id journal-id-type="iso-abbrev">Liver Int</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">LIV</journal-id><journal-title-group><journal-title>Liver International</journal-title></journal-title-group><issn pub-type="ppub">1478-3223</issn><issn pub-type="epub">1478-3231</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11892336</article-id><article-id pub-id-type="pmcid-ver">PMC11892336.1</article-id><article-id pub-id-type="pmcaid">11892336</article-id><article-id pub-id-type="pmcaiid">11892336</article-id><article-id pub-id-type="pmid">39403816</article-id><article-id pub-id-type="doi">10.1111/liv.16132</article-id><article-id pub-id-type="publisher-id">LIV16132</article-id><article-id pub-id-type="other">LIVint-24-01618.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Impact of <styled-content style="fixed-case" toggle="no">GLP</styled-content>&#8208;<styled-content style="fixed-case" toggle="no">1RA</styled-content> on the Risk of Adverse Liver Outcomes Among Patients With Alcohol&#8208;Associated Liver Disease and Type 2 Diabetes</article-title></title-group><contrib-group><contrib id="liv16132-cr-0001" contrib-type="author"><name name-style="western"><surname>Rashid</surname><given-names initials="Z">Zayed</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0000-0500-8325</contrib-id><xref rid="liv16132-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="liv16132-cr-0002" contrib-type="author"><name name-style="western"><surname>Woldesenbet</surname><given-names initials="S">Selamawit</given-names></name><xref rid="liv16132-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="liv16132-cr-0003" contrib-type="author"><name name-style="western"><surname>Khalil</surname><given-names initials="M">Mujtaba</given-names></name><xref rid="liv16132-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="liv16132-cr-0004" contrib-type="author"><name name-style="western"><surname>Iyer</surname><given-names initials="S">Sidharth</given-names></name><xref rid="liv16132-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="liv16132-cr-0005" contrib-type="author"><name name-style="western"><surname>Khan</surname><given-names initials="MMM">Muhammad Muntazir Mehdi</given-names></name><xref rid="liv16132-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="liv16132-cr-0006" contrib-type="author"><name name-style="western"><surname>Altaf</surname><given-names initials="A">Abdullah</given-names></name><xref rid="liv16132-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="liv16132-cr-0007" contrib-type="author"><name name-style="western"><surname>Munir</surname><given-names initials="MM">Muhammad Musaab</given-names></name><xref rid="liv16132-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="liv16132-cr-0008" contrib-type="author"><name name-style="western"><surname>Catalano</surname><given-names initials="G">Giovanni</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1440-7031</contrib-id><xref rid="liv16132-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="liv16132-cr-0009" contrib-type="author"><name name-style="western"><surname>Mumtaz</surname><given-names initials="K">Khalid</given-names></name><xref rid="liv16132-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="liv16132-cr-0010" contrib-type="author" corresp="yes"><name name-style="western"><surname>Pawlik</surname><given-names initials="TM">Timothy M.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7994-9870</contrib-id><xref rid="liv16132-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>tim.pawlik@osumc.edu</email></address></contrib></contrib-group><aff id="liv16132-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Surgery</named-content>
<institution>The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center</institution>
<city>Columbus</city>
<named-content content-type="country-part">Ohio</named-content>
<country country="US">USA</country>
</aff><aff id="liv16132-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine</named-content>
<institution>College of Medicine, The Ohio State University</institution>
<city>Columbus</city>
<named-content content-type="country-part">Ohio</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Timothy M. Pawlik (<email>tim.pawlik@osumc.edu</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2025</year></pub-date><volume>45</volume><issue seq="460">4</issue><issue-id pub-id-type="pmc-issue-id">483790</issue-id><issue-id pub-id-type="doi">10.1111/liv.v45.4</issue-id><elocation-id>e16132</elocation-id><history><date date-type="rev-recd"><day>18</day><month>9</month><year>2024</year></date><date date-type="received"><day>02</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>01</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>11</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-11 10:25:16.343"><day>11</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2024 The Author(s). <italic toggle="yes">Liver International</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="LIV-45-0.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:LIV-45-0.pdf"/><abstract><title>ABSTRACT</title><sec id="liv16132-sec-0001"><title>Background and Aims</title><p>We sought to characterise the impact of GLP&#8208;1RA on adverse liver outcomes (ALO) among patients with alcohol&#8208;associated liver disease (ALD) and Type 2 diabetes mellitus (T2DM).</p></sec><sec id="liv16132-sec-0002"><title>Methods</title><p>Patients with T2DM newly diagnosed with ALD between 2013 and 2020 were identified using IBM MarketScan database and were categorised by GLP&#8208;1RA exposure. Overlap propensity score weighting (OPSW) followed by Poisson regression models was used to analyse adjusted risk of ALO, a composite endpoint defined by first occurrence of hepatic decompensation (HD), portal hypertension (PH), hepatocellular carcinoma (HCC) or liver transplantation (LT) relative to GLP&#8208;1RA.</p></sec><sec id="liv16132-sec-0003"><title>Results</title><p>Among 14&#8201;730 patients, most individuals were male (<italic toggle="no">n</italic>&#8201;=&#8201;9752, 66.2%) with median age of 57 (IQR 52&#8211;61) years; 2.2% (<italic toggle="no">n</italic>&#8201;=&#8201;317) of patients had GLP&#8208;1RA exposure. Overall, 32.0% (<italic toggle="no">n</italic>&#8201;=&#8201;4717) of patients experienced HD, 15.9% (<italic toggle="no">n</italic>&#8201;=&#8201;2345) had PH, 3.8% (<italic toggle="no">n</italic>&#8201;=&#8201;563) developed HCC, while 2.5% (<italic toggle="no">n</italic>&#8201;=&#8201;374) underwent transplantation. Non&#8208;GLP&#8208;1RA patients had higher incidence of HD (32.2% vs. 22.4%) and HCC (3.9% vs. 0.3%) versus patients taking GLP&#8208;1RA (both <italic toggle="no">p</italic>&#8201;&lt;&#8201;0.001); in contrast, there was no difference in incidence of PH (14.5% vs. 16.0%) and LT (1.3% vs. 2.6%) (both <italic toggle="no">p</italic>&#8201;&gt;&#8201;0.05). After OPSW, overall incidence of ALO was lower in GLP&#8208;1RA cohort (GLP&#8208;1RA: 12.0%, 95%CI 9.0&#8211;16.0 vs. non&#8208;GLP&#8208;1RA: 21.0%, 95%CI 20.0&#8211;22.0) with an absolute incidence risk reduction of 9.0% (95%CI 3.0%&#8211;15.0%) associated with GLP&#8208;1RA. GLP&#8208;1RA was most strongly associated with lower likelihood of HD with reduced adjusted incidence rate of 0.56 (95%CI 0.36&#8211;0.86) relative to non&#8208;GLP&#8208;1RA individuals.</p></sec><sec id="liv16132-sec-0004"><title>Conclusions</title><p>GLP&#8208;1RA may have a hepatoprotective impact among patients with ALD and T2DM.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="liv16132-kwd-0001">ALD</kwd><kwd id="liv16132-kwd-0002">diabetes mellitus</kwd><kwd id="liv16132-kwd-0003">GLP&#8208;1RA</kwd><kwd id="liv16132-kwd-0004">hepatic decompensation</kwd><kwd id="liv16132-kwd-0005">hepatocellular carcinoma</kwd></kwd-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="13"/><word-count count="7600"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:10.03.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="liv16132-ntgp-0001"><fn fn-type="funding" id="liv16132-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn><fn fn-type="generalState" id="liv16132-note-0002"><p>This paper has been accepted as an oral presentation in plenary session of the AASLD meeting to be held in San Diego, California, from 15 to 19 November.</p></fn></fn-group></notes></front><body id="liv16132-body-0001"><def-list list-content="abbreviations" id="liv16132-dl-0001"><title>Abbreviations</title><def-item><term id="liv16132-li-0001">AIDS</term><def id="liv16132-li-0002"><p>acquired immunodeficiency syndrome</p></def></def-item><def-item><term id="liv16132-li-0003">ALD</term><def id="liv16132-li-0004"><p>alcohol&#8208;associated liver disease</p></def></def-item><def-item><term id="liv16132-li-0005">ALO</term><def id="liv16132-li-0006"><p>adverse liver outcomes</p></def></def-item><def-item><term id="liv16132-li-0007">CCI</term><def id="liv16132-li-0008"><p>Charlson Comorbidity Index</p></def></def-item><def-item><term id="liv16132-li-0009">COBRA</term><def id="liv16132-li-0010"><p>Consolidated Omnibus Budget Reconciliation Act</p></def></def-item><def-item><term id="liv16132-li-0011">Diff</term><def id="liv16132-li-0012"><p>difference</p></def></def-item><def-item><term id="liv16132-li-0013">DPP&#8208;4</term><def id="liv16132-li-0014"><p>dipeptidyl peptidase&#8208;4 inhibitors</p></def></def-item><def-item><term id="liv16132-li-0015">GLP&#8208;1RA</term><def id="liv16132-li-0016"><p>glucagon&#8208;like peptide&#8208;1 receptor agonists</p></def></def-item><def-item><term id="liv16132-li-0017">HD</term><def id="liv16132-li-0018"><p>hepatic decompensation</p></def></def-item><def-item><term id="liv16132-li-0019">HCC</term><def id="liv16132-li-0020"><p>hepatocellular carcinoma</p></def></def-item><def-item><term id="liv16132-li-0021">HMO</term><def id="liv16132-li-0022"><p>health maintenance organisations</p></def></def-item><def-item><term id="liv16132-li-0023">ICD</term><def id="liv16132-li-0024"><p>international classification of diseases</p></def></def-item><def-item><term id="liv16132-li-0025">IQR</term><def id="liv16132-li-0026"><p>interquartile range</p></def></def-item><def-item><term id="liv16132-li-0027">LT</term><def id="liv16132-li-0028"><p>liver transplantation</p></def></def-item><def-item><term id="liv16132-li-0029">MASH</term><def id="liv16132-li-0030"><p>metabolic dysfunction&#8208;associated steatohepatitis</p></def></def-item><def-item><term id="liv16132-li-0031">OPSW</term><def id="liv16132-li-0032"><p>overlap propensity score weighting</p></def></def-item><def-item><term id="liv16132-li-0033">PH</term><def id="liv16132-li-0034"><p>portal hypertension</p></def></def-item><def-item><term id="liv16132-li-0035">RAAS</term><def id="liv16132-li-0036"><p>renin&#8211;angiotensin&#8211;aldosterone axis</p></def></def-item><def-item><term id="liv16132-li-0037">SBP</term><def id="liv16132-li-0038"><p>spontaneous bacterial peritonitis</p></def></def-item><def-item><term id="liv16132-li-0039">SD</term><def id="liv16132-li-0040"><p>standard deviation</p></def></def-item><def-item><term id="liv16132-li-0041">STROBE</term><def id="liv16132-li-0042"><p>strengthening the reporting of observational studies in epidemiology</p></def></def-item><def-item><term id="liv16132-li-0043">T2DM</term><def id="liv16132-li-0044"><p>type 2 diabetes mellitus</p></def></def-item><def-item><term id="liv16132-li-0045">US</term><def id="liv16132-li-0046"><p>United States</p></def></def-item></def-list><p>
<boxed-text position="anchor" content-type="box" id="liv16132-blkfxd-0001" orientation="portrait"><caption><title>Summary</title></caption><p>
<list list-type="bullet" id="liv16132-list-0001"><list-item id="liv16132-li-0047"><p>We sought to study impact of GLP&#8208;1RA on adverse liver outcomes among patients with alcohol&#8208;associated liver disease (ALD) and T2DM.</p></list-item><list-item id="liv16132-li-0048"><p>GLP&#8208;1RA can potentially mitigate the risk of adverse liver outcomes, particularly decompensation, among patients with ALD.</p></list-item><list-item id="liv16132-li-0049"><p>Randomised controlled trials are needed to prove the role of GLP&#8208;1RA among patients with ALD and T2DM.</p></list-item><list-item id="liv16132-li-0050"><p>Healthcare organisations and policymakers should focus on improving access to this broad&#8208;spectrum class of drugs for patients with diabetes.</p></list-item></list>
</p></boxed-text>
</p><sec id="liv16132-sec-0007"><label>1</label><title>Introduction</title><p>Alcohol&#8208;associated liver disease (ALD) is a frequent complication of excessive alcohol intake that can encompass a spectrum of conditions from steatosis, acute inflammation and cirrhosis that may lead to hepatocellular carcinoma (HCC) [<xref rid="liv16132-bib-0001" ref-type="bibr">1</xref>, <xref rid="liv16132-bib-0002" ref-type="bibr">2</xref>]. Over the past two decades, half a million individuals have died from alcohol&#8208;related causes with more than 60% of these deaths attributed to liver disease alone [<xref rid="liv16132-bib-0003" ref-type="bibr">3</xref>]. During the COVID&#8208;19 pandemic, online alcohol sales surged by more than 200%, accompanied by an approximately 40% rise in alcohol consumption, which further contributed to a spike in alcohol&#8208;related health disorders [<xref rid="liv16132-bib-0004" ref-type="bibr">4</xref>, <xref rid="liv16132-bib-0005" ref-type="bibr">5</xref>]. The burden of liver disease is even greater among patients with diabetes with potentially higher risk of hepatic complications [<xref rid="liv16132-bib-0006" ref-type="bibr">6</xref>]. In fact, patients with diabetes and concurrent diseases such as metabolic dysfunction&#8208;associated steatohepatitis (MASH) and chronic hepatitis have a twofold higher risk of decompensation [<xref rid="liv16132-bib-0007" ref-type="bibr">7</xref>]. As such, there has been increased interest in examining the relationship of ALD with diabetes, as well as characterising optimal management approaches in clinical practice.</p><p>The metabolism of ethanol to acetaldehyde and eventually to acetate can cause a redox shift by impairing the NADH/NAD ratio [<xref rid="liv16132-bib-0008" ref-type="bibr">8</xref>]. This shift can disrupt metabolic pathways such as gluconeogenesis, glycogenolysis and the &#946;&#8208;oxidation of fatty acids, potentially leading to ALD [<xref rid="liv16132-bib-0009" ref-type="bibr">9</xref>]. Owing to the shared pathogenesis of altered metabolism of glucose as well as lipids, a strong reciprocal relationship exists between diabetes and alcohol&#8208;related liver pathologies [<xref rid="liv16132-bib-0010" ref-type="bibr">10</xref>, <xref rid="liv16132-bib-0011" ref-type="bibr">11</xref>]. Additionally, incretins such as glucagon&#8208;like peptide&#8208;1 are commonly implicated in food regulation with glycaemic control and may share neuronal pathways related to alcohol&#8208;mediated behaviours [<xref rid="liv16132-bib-0012" ref-type="bibr">12</xref>]. A relatively newer class of antiglycaemic drugs, including glucagon&#8208;like peptide&#8208;1 receptor agonists (GLP&#8208;1RAs), targets the incretin pathways and has become popular for managing diabetes [<xref rid="liv16132-bib-0010" ref-type="bibr">10</xref>, <xref rid="liv16132-bib-0013" ref-type="bibr">13</xref>]. Previous studies have demonstrated that this class of medications can reduce aminotransferase levels among patients with metabolic&#8208;associated fatty liver disease, suggesting benefits beyond diabetes management [<xref rid="liv16132-bib-0013" ref-type="bibr">13</xref>]. These benefits may be due to associated weight reduction, decreased inflammatory markers and reduced lipotoxicity [<xref rid="liv16132-bib-0010" ref-type="bibr">10</xref>, <xref rid="liv16132-bib-0014" ref-type="bibr">14</xref>]. Furthermore, Quddos et&#160;al. reported that semaglutide and tirzepatide are linked to decreased alcohol consumption among patients with obesity [<xref rid="liv16132-bib-0012" ref-type="bibr">12</xref>].</p><p>To date, the clinical evidence of the effectiveness of GLP&#8208;1RA medications among patients with ALD remains ill&#8208;defined. Patients with severe ALD such as cirrhosis are often excluded from randomised controlled trials due to safety concerns, underscoring a need for an observational study [<xref rid="liv16132-bib-0015" ref-type="bibr">15</xref>]. Therefore, the objective of the current study was to characterise the impact of GLP&#8208;1RAs on adverse liver outcomes (ALO) among patients with ALD and Type 2 diabetes mellitus (T2DM).</p></sec><sec sec-type="methods" id="liv16132-sec-0008"><label>2</label><title>Methods</title><p>This retrospective cohort study utilised the IBM MarketScan database, a comprehensive national dataset containing longitudinal individual&#8208;level information on privately insured patients across inpatient, outpatient and prescription drug services [<xref rid="liv16132-bib-0016" ref-type="bibr">16</xref>]. The database has been previously validated to study epidemiological and clinical outcomes [<xref rid="liv16132-bib-0017" ref-type="bibr">17</xref>, <xref rid="liv16132-bib-0018" ref-type="bibr">18</xref>]. The International Classification of Diseases, ninth and tenth editions (ICD&#8208;9/10) codes, identified patients under 65&#8201;years of age with T2DM, who had at least one inpatient and two outpatient diagnoses of ALD from 2013 to 2020 (Table&#160;<xref rid="liv16132-supitem-0001" ref-type="supplementary-material">S1</xref>) [<xref rid="liv16132-bib-0019" ref-type="bibr">19</xref>]. The index date of diagnosis was defined as the first record of ALD following 12 months of continuous enrolment in an insurance plan. Similarly, patients with prior exposure to GLP&#8208;1RA before the index diagnosis of ALD and individuals with other liver conditions were excluded (Figure&#160;<xref rid="liv16132-fig-0001" ref-type="fig">1</xref>). The national drug codes were employed to query the pharmaceutical records to identify patients who had at least one claim for GLP&#8208;1RAs therapy (semaglutide, albiglutide, liraglutide, dulaglutide, lixisenatide or exenatide) within a year after the index diagnosis of ALD. The remaining cohort undergoing routine care was characterised as the non&#8208;GLP&#8208;1RA group. The study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines. The current study was deemed exempt from approval by the Institutional Review Board at Ohio State University since the IBM Marketscan database meets the criteria for limited&#8208;use data.</p><fig position="float" fig-type="FIGURE" id="liv16132-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Flowchart depicting the number of patients included according to the study criteria.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="LIV-45-0-g001.jpg"/></fig><sec id="liv16132-sec-0009"><label>2.1</label><title>Variables and Exposure</title><p>Variables of interest included patient age, sex, Charlson Comorbidity Index (CCI), claim&#8208;based frailty index, employment status, benefit plan type, US census region (northeast, northcentral, south and west) and baseline concurrent medical conditions (Table&#160;<xref rid="liv16132-tbl-0001" ref-type="table">1</xref>). The CCI was calculated after excluding mild and moderate&#8208;to&#8208;severe liver disease along with diabetes without chronic complications and was categorised as previously defined [<xref rid="liv16132-bib-0020" ref-type="bibr">20</xref>, <xref rid="liv16132-bib-0021" ref-type="bibr">21</xref>, <xref rid="liv16132-bib-0022" ref-type="bibr">22</xref>]. The claim&#8208;based frailty index is a measure of deficit accumulation frailty within the prior 12 months, estimated from the administrative dataset using Current Procedural Terminology Codes, Healthcare Common Procedure Coding System Codes and ICD codes&#160;[<xref rid="liv16132-bib-0023" ref-type="bibr">23</xref>]. Patients were grouped into three categories based on their employment status: retired, actively employed and &#8216;Other&#8217;. The &#8216;Other&#8217; category included dependents, individuals with long&#8208;term disabilities and Consolidated Omnibus Budget Reconciliation Act (COBRA) continuers. Additionally, ICD&#8208;9/10 codes identified any concurrent baseline medical conditions related to the cardiovascular, central nervous and gastrointestinal systems (Table&#160;<xref rid="liv16132-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="liv16132-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Baseline characteristics of patients with alcoholic liver disease with type 2 diabetes by glucagon&#8208;like peptide&#8208;1 receptor agonists initiation status.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1"/><th align="center" colspan="4" valign="bottom" rowspan="1">Unweighted</th><th align="center" colspan="4" valign="bottom" rowspan="1">Weighted<xref rid="liv16132-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Patient characteristics</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total <italic toggle="yes">N</italic>&#8201;=&#8201;14&#8201;730</th><th align="center" valign="bottom" rowspan="1" colspan="1">GLP&#8208;1RA <italic toggle="yes">N</italic>&#8201;=&#8201;317 (2.2%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Non&#8208;GLP&#8208;1RA <italic toggle="yes">N</italic>&#8201;=&#8201;14&#8201;413 (97.8%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Standard diff.<xref rid="liv16132-note-0005" ref-type="table-fn">
<sup>b</sup>
</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">GLP&#8208;1RA (%)<xref rid="liv16132-note-0006" ref-type="table-fn">
<sup>c</sup>
</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Non&#8208;GLP&#8208;1RA (%)<xref rid="liv16132-note-0006" ref-type="table-fn">
<sup>c</sup>
</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Standard diff.<xref rid="liv16132-note-0006" ref-type="table-fn">
<sup>c</sup>
</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, years</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">55.3&#8201;&#177;&#8201;6.3</td><td align="center" valign="top" rowspan="1" colspan="1">54.7&#8201;&#177;&#8201;6.6</td><td align="center" valign="top" rowspan="1" colspan="1">55.8&#8201;&#177;&#8201;7.3</td><td align="center" valign="top" rowspan="1" colspan="1">15.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.005</td><td align="center" valign="top" rowspan="1" colspan="1">54.8&#8201;&#177;&#8201;6.1</td><td align="center" valign="top" rowspan="1" colspan="1">54.7&#8201;&#177;&#8201;1.0</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.022</td><td align="center" valign="top" rowspan="1" colspan="1">0.100</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median (IQR)</td><td align="center" valign="top" rowspan="1" colspan="1">57 (52&#8211;61)</td><td align="center" valign="top" rowspan="1" colspan="1">56 (51&#8211;60)</td><td align="center" valign="top" rowspan="1" colspan="1">58 (52&#8211;61)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;1.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.005</td><td align="center" valign="top" rowspan="1" colspan="1">56 (51&#8211;60)</td><td align="center" valign="top" rowspan="1" colspan="1">56 (51&#8211;60)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.022</td><td align="center" valign="top" rowspan="1" colspan="1">0.100</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">9752 (66.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">158 (49.8)</td><td align="center" valign="top" rowspan="1" colspan="1">9594 (66.6)</td><td align="center" valign="top" rowspan="1" colspan="1">34.6</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">49.8</td><td align="center" valign="top" rowspan="1" colspan="1">50.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.020</td><td align="center" valign="top" rowspan="1" colspan="1">0.810</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">4978 (33.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">159 (50.2)</td><td align="center" valign="top" rowspan="1" colspan="1">4819 (33.4)</td><td align="center" valign="top" rowspan="1" colspan="1">34.6</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">50.2</td><td align="center" valign="top" rowspan="1" colspan="1">49.2</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.020</td><td align="center" valign="top" rowspan="1" colspan="1">0.810</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Region</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Northeast</td><td align="center" valign="top" rowspan="1" colspan="1">2839 (19.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">51 (16.1)</td><td align="center" valign="top" rowspan="1" colspan="1">2788 (19.3)</td><td align="center" valign="top" rowspan="1" colspan="1">8.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">16.1</td><td align="center" valign="top" rowspan="1" colspan="1">16.7</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.016</td><td align="center" valign="top" rowspan="1" colspan="1">0.260</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">North Central</td><td align="center" valign="top" rowspan="1" colspan="1">2757 (18.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">71 (22.4)</td><td align="center" valign="top" rowspan="1" colspan="1">2686 (18.6)</td><td align="center" valign="top" rowspan="1" colspan="1">9.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">22.4</td><td align="center" valign="top" rowspan="1" colspan="1">18.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.087</td><td align="center" valign="top" rowspan="1" colspan="1">0.260</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">South</td><td align="center" valign="top" rowspan="1" colspan="1">6738 (45.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">166 (52.4)</td><td align="center" valign="top" rowspan="1" colspan="1">6572 (45.6)</td><td align="center" valign="top" rowspan="1" colspan="1">13.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">50.4</td><td align="center" valign="top" rowspan="1" colspan="1">50.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.006</td><td align="center" valign="top" rowspan="1" colspan="1">0.260</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">West</td><td align="center" valign="top" rowspan="1" colspan="1">2294 (15.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (9.1)</td><td align="center" valign="top" rowspan="1" colspan="1">2265 (15.7)</td><td align="center" valign="top" rowspan="1" colspan="1">20.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">11.1</td><td align="center" valign="top" rowspan="1" colspan="1">14</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.088</td><td align="center" valign="top" rowspan="1" colspan="1">0.260</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Type of health insurance</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">PPO</td><td align="center" valign="top" rowspan="1" colspan="1">8224 (55.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">173 (54.6)</td><td align="center" valign="top" rowspan="1" colspan="1">8051 (55.9)</td><td align="center" valign="top" rowspan="1" colspan="1">2.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.038</td><td align="center" valign="top" rowspan="1" colspan="1">54.6</td><td align="center" valign="top" rowspan="1" colspan="1">53.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.020</td><td align="center" valign="top" rowspan="1" colspan="1">0.470</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">HMO</td><td align="center" valign="top" rowspan="1" colspan="1">1916 (13.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">30 (9.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1886 (13.1)</td><td align="center" valign="top" rowspan="1" colspan="1">11.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.038</td><td align="center" valign="top" rowspan="1" colspan="1">10.5</td><td align="center" valign="top" rowspan="1" colspan="1">13.5</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.092</td><td align="center" valign="top" rowspan="1" colspan="1">0.470</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Comprehensive</td><td align="center" valign="top" rowspan="1" colspan="1">802 (5.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (4.4)</td><td align="center" valign="top" rowspan="1" colspan="1">788 (5.5)</td><td align="center" valign="top" rowspan="1" colspan="1">5.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.038</td><td align="center" valign="top" rowspan="1" colspan="1">4.4</td><td align="center" valign="top" rowspan="1" colspan="1">5.1</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.033</td><td align="center" valign="top" rowspan="1" colspan="1">0.470</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">POS</td><td align="center" valign="top" rowspan="1" colspan="1">969 (6.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (6.3)</td><td align="center" valign="top" rowspan="1" colspan="1">949 (6.6)</td><td align="center" valign="top" rowspan="1" colspan="1">1.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.038</td><td align="center" valign="top" rowspan="1" colspan="1">6.3</td><td align="center" valign="top" rowspan="1" colspan="1">6.8</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.020</td><td align="center" valign="top" rowspan="1" colspan="1">0.470</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other<xref rid="liv16132-note-0007" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">2819 (19.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">80 (25.2)</td><td align="center" valign="top" rowspan="1" colspan="1">2739 (19.0)</td><td align="center" valign="top" rowspan="1" colspan="1">15.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.038</td><td align="center" valign="top" rowspan="1" colspan="1">24.2</td><td align="center" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">0.077</td><td align="center" valign="top" rowspan="1" colspan="1">0.470</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Employment status</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other</td><td align="center" valign="top" rowspan="1" colspan="1">7769 (52.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">199 (62.8)</td><td align="center" valign="top" rowspan="1" colspan="1">7570 (52.5)</td><td align="center" valign="top" rowspan="1" colspan="1">21.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">62.8</td><td align="center" valign="top" rowspan="1" colspan="1">58.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.080</td><td align="center" valign="top" rowspan="1" colspan="1">0.310</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Full/part&#8208;time</td><td align="center" valign="top" rowspan="1" colspan="1">2336 (15.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">45 (14.2)</td><td align="center" valign="top" rowspan="1" colspan="1">2291 (15.9)</td><td align="center" valign="top" rowspan="1" colspan="1">4.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">12.2</td><td align="center" valign="top" rowspan="1" colspan="1">12.7</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.015</td><td align="center" valign="top" rowspan="1" colspan="1">0.310</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Retired</td><td align="center" valign="top" rowspan="1" colspan="1">4625 (31.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">73 (23.0)</td><td align="center" valign="top" rowspan="1" colspan="1">4552 (31.6)</td><td align="center" valign="top" rowspan="1" colspan="1">19.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">25.0</td><td align="center" valign="top" rowspan="1" colspan="1">28.4</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.077</td><td align="center" valign="top" rowspan="1" colspan="1">0.310</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CCI</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">8639 (58.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">191 (60.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">8448 (58.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">7.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.183</td><td align="center" valign="top" rowspan="1" colspan="1">60.3</td><td align="center" valign="top" rowspan="1" colspan="1">60</td><td align="center" valign="top" rowspan="1" colspan="1">0.006</td><td align="center" valign="top" rowspan="1" colspan="1">0.800</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">1&#8211;2</td><td align="center" valign="top" rowspan="1" colspan="1">3595 (24.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">84 (26.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">3511 (24.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">10.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.183</td><td align="center" valign="top" rowspan="1" colspan="1">26.5</td><td align="center" valign="top" rowspan="1" colspan="1">24.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.033</td><td align="center" valign="top" rowspan="1" colspan="1">0.800</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">3&#8211;4</td><td align="center" valign="top" rowspan="1" colspan="1">1290 (8.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (8.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">1263 (8.8)</td><td align="center" valign="top" rowspan="1" colspan="1">2.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.183</td><td align="center" valign="top" rowspan="1" colspan="1">8.5</td><td align="center" valign="top" rowspan="1" colspan="1">8.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.015</td><td align="center" valign="top" rowspan="1" colspan="1">0.800</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">5+</td><td align="center" valign="top" rowspan="1" colspan="1">1206 (8.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (4.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">1191 (8.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">14.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.183</td><td align="center" valign="top" rowspan="1" colspan="1">4.7</td><td align="center" valign="top" rowspan="1" colspan="1">6.8</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.090</td><td align="center" valign="top" rowspan="1" colspan="1">0.800</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Claim&#8208;based frailty index</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Nonfrail</td><td align="center" valign="top" rowspan="1" colspan="1">6993 (47.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">134 (42.3)</td><td align="center" valign="top" rowspan="1" colspan="1">6859 (47.6)</td><td align="center" valign="top" rowspan="1" colspan="1">10.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.030</td><td align="center" valign="top" rowspan="1" colspan="1">42.9</td><td align="center" valign="top" rowspan="1" colspan="1">46.6</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.074</td><td align="center" valign="top" rowspan="1" colspan="1">0.310</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Prefrail</td><td align="center" valign="top" rowspan="1" colspan="1">7021 (47.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">173 (54.6)</td><td align="center" valign="top" rowspan="1" colspan="1">6848 (47.5)</td><td align="center" valign="top" rowspan="1" colspan="1">14.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.030</td><td align="center" valign="top" rowspan="1" colspan="1">53.8</td><td align="center" valign="top" rowspan="1" colspan="1">48.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.098</td><td align="center" valign="top" rowspan="1" colspan="1">0.310</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Frail</td><td align="center" valign="top" rowspan="1" colspan="1">716 (4.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (3.2)</td><td align="center" valign="top" rowspan="1" colspan="1">706 (4.9)</td><td align="center" valign="top" rowspan="1" colspan="1">8.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.030</td><td align="center" valign="top" rowspan="1" colspan="1">3.3</td><td align="center" valign="top" rowspan="1" colspan="1">4.5</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.062</td><td align="center" valign="top" rowspan="1" colspan="1">0.310</td></tr></tbody></table><table-wrap-foot id="liv16132-ntgp-0002"><fn id="liv16132-note-0003"><p>Abbreviations: CCI, Charlson Comorbidity Index; diff, difference; GLP&#8208;1RA, glucagon&#8208;like peptide&#8208;1 receptor agonist; IQR, interquartile range; SD, standard deviation.</p></fn><fn id="liv16132-note-0004"><label>
<sup>a</sup>
</label><p>Pseudosample was created using the overlap weighting technique, ensuring that GLP&#8208;1RA initiation is independent of other clinicodemographic characteristics of the patients.</p></fn><fn id="liv16132-note-0005"><label>
<sup>b</sup>
</label><p>Absolute difference in means/proportions divided by pooled SD. The absolute value greater than 0.10 represented an imbalance between two study groups; smaller values indicate better balance.</p></fn><fn id="liv16132-note-0006"><label>
<sup>c</sup>
</label><p>Overlap weighted proportions and standardised differences were calculated using all patient demographics and medical history.</p></fn><fn id="liv16132-note-0007"><label>
<sup>d</sup>
</label><p>Including, COBRA, long&#8208;term disability, surviving spouse/dependent or other/unknown.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="liv16132-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Additional clinical characteristics of patients with alcoholic liver disease with type 2 diabetes by glucagon&#8208;like peptide&#8208;1 receptor agonists initiation.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1"/><th align="center" colspan="4" valign="bottom" rowspan="1">Unweighted</th><th align="center" colspan="4" valign="bottom" rowspan="1">Weighted<xref rid="liv16132-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Patient characteristics</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total <italic toggle="yes">N</italic>&#8201;=&#8201;14&#8201;730</th><th align="center" valign="bottom" rowspan="1" colspan="1">GLP&#8208;1RA <italic toggle="yes">N</italic>&#8201;=&#8201;317 (2.2%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Non&#8208;GLP&#8208;1RA <italic toggle="yes">N</italic>&#8201;=&#8201;14&#8201;413 (97.8%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Standard diff.<xref rid="liv16132-note-0010" ref-type="table-fn">
<sup>b</sup>
</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">GLP&#8208;1RA (%)<xref rid="liv16132-note-0011" ref-type="table-fn">
<sup>c</sup>
</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Non&#8208;GLP&#8208;1RA (%)<xref rid="liv16132-note-0011" ref-type="table-fn">
<sup>c</sup>
</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Standard diff.<xref rid="liv16132-note-0011" ref-type="table-fn">
<sup>c</sup>
</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Myocardial infarction</td><td align="center" valign="top" rowspan="1" colspan="1">328 (2.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (0.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">326 (2.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">14.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.052</td><td align="center" valign="top" rowspan="1" colspan="1">1.6</td><td align="center" valign="top" rowspan="1" colspan="1">2.1</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.037</td><td align="center" valign="top" rowspan="1" colspan="1">0.110</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Congestive heart failure</td><td align="center" valign="top" rowspan="1" colspan="1">1220 (8.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (4.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">1206 (8.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">16.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.012</td><td align="center" valign="top" rowspan="1" colspan="1">5.4</td><td align="center" valign="top" rowspan="1" colspan="1">7.7</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.093</td><td align="center" valign="top" rowspan="1" colspan="1">0.090</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Peripheral vascular disease</td><td align="center" valign="top" rowspan="1" colspan="1">628 (4.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (2.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">620 (4.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">9.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.121</td><td align="center" valign="top" rowspan="1" colspan="1">2.5</td><td align="center" valign="top" rowspan="1" colspan="1">3.6</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.064</td><td align="center" valign="top" rowspan="1" colspan="1">0.430</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cerebrovascular disease</td><td align="center" valign="top" rowspan="1" colspan="1">475 (3.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (2.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">467 (3.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">4.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.475</td><td align="center" valign="top" rowspan="1" colspan="1">2.5</td><td align="center" valign="top" rowspan="1" colspan="1">3.2</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.042</td><td align="center" valign="top" rowspan="1" colspan="1">0.640</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dementia</td><td align="center" valign="top" rowspan="1" colspan="1">36 (0.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">36 (0.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">418.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.373</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0.3</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.078</td><td align="center" valign="top" rowspan="1" colspan="1">0.350</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hemiplagia or paraplegia</td><td align="center" valign="top" rowspan="1" colspan="1">73 (0.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">72 (0.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">3.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.644</td><td align="center" valign="top" rowspan="1" colspan="1">0.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.5</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.032</td><td align="center" valign="top" rowspan="1" colspan="1">0.740</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes with complications</td><td align="center" valign="top" rowspan="1" colspan="1">2585 (17.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">68 (21.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">2517 (17.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">10.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.065</td><td align="center" valign="top" rowspan="1" colspan="1">21.5</td><td align="center" valign="top" rowspan="1" colspan="1">18.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.067</td><td align="center" valign="top" rowspan="1" colspan="1">0.420</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypertension</td><td align="center" valign="top" rowspan="1" colspan="1">9917 (67.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">219 (69.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">9698 (67.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">3.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.499</td><td align="center" valign="top" rowspan="1" colspan="1">69.1</td><td align="center" valign="top" rowspan="1" colspan="1">68.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.019</td><td align="center" valign="top" rowspan="1" colspan="1">0.810</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Obesity</td><td align="center" valign="top" rowspan="1" colspan="1">1259 (8.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">52 (16.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">1207 (8.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">24.5</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">16.4</td><td align="center" valign="top" rowspan="1" colspan="1">15.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.022</td><td align="center" valign="top" rowspan="1" colspan="1">0.790</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dyslipidaemia</td><td align="center" valign="top" rowspan="1" colspan="1">8435 (57.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">198 (62.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">8237 (57.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">11.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.059</td><td align="center" valign="top" rowspan="1" colspan="1">62.5</td><td align="center" valign="top" rowspan="1" colspan="1">59.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.070</td><td align="center" valign="top" rowspan="1" colspan="1">0.400</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Renal disease</td><td align="center" valign="top" rowspan="1" colspan="1">1344 (9.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (5.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">1326 (9.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">13.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.031</td><td align="center" valign="top" rowspan="1" colspan="1">5.7</td><td align="center" valign="top" rowspan="1" colspan="1">7.6</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.076</td><td align="center" valign="top" rowspan="1" colspan="1">0.350</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chronic pulmonary disease</td><td align="center" valign="top" rowspan="1" colspan="1">1429 (9.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">34 (10.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">1395 (9.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">3.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.533</td><td align="center" valign="top" rowspan="1" colspan="1">10.7</td><td align="center" valign="top" rowspan="1" colspan="1">9.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.033</td><td align="center" valign="top" rowspan="1" colspan="1">0.690</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Peptic ulcer disease</td><td align="center" valign="top" rowspan="1" colspan="1">217 (1.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (1.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">213 (1.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">1.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.752</td><td align="center" valign="top" rowspan="1" colspan="1">1.3</td><td align="center" valign="top" rowspan="1" colspan="1">1.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.009</td><td align="center" valign="top" rowspan="1" colspan="1">0.970</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rheumatic disease</td><td align="center" valign="top" rowspan="1" colspan="1">287 (1.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (3.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">276 (1.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">9.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.048</td><td align="center" valign="top" rowspan="1" colspan="1">3.5</td><td align="center" valign="top" rowspan="1" colspan="1">2.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.072</td><td align="center" valign="top" rowspan="1" colspan="1">0.380</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AIDS/HIV</td><td align="center" valign="top" rowspan="1" colspan="1">107 (0.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">106 (0.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">5.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.384</td><td align="center" valign="top" rowspan="1" colspan="1">0.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.7</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.057</td><td align="center" valign="top" rowspan="1" colspan="1">0.550</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No&#160;malignancy</td><td align="center" valign="top" rowspan="1" colspan="1">13&#8201;163 (89.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">295 (93.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">12&#8201;868 (89.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">13.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.031</td><td align="center" valign="top" rowspan="1" colspan="1">6.9</td><td align="center" valign="top" rowspan="1" colspan="1">8.3</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.053</td><td align="center" valign="top" rowspan="1" colspan="1">0.520</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Metastatic solid tumour</td><td align="center" valign="top" rowspan="1" colspan="1">399 (2.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (1.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">395 (2.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">10.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.109</td><td align="center" valign="top" rowspan="1" colspan="1">1.3</td><td align="center" valign="top" rowspan="1" colspan="1">2.0</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.055</td><td align="center" valign="top" rowspan="1" colspan="1">0.490</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Combination drugs</td><td align="center" valign="top" rowspan="1" colspan="1">238 (1.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (3.8)</td><td align="center" valign="top" rowspan="1" colspan="1">426 (3.0)</td><td align="center" valign="top" rowspan="1" colspan="1">4.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.390</td><td align="center" valign="top" rowspan="1" colspan="1">3.8</td><td align="center" valign="top" rowspan="1" colspan="1">3.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.038</td><td align="center" valign="top" rowspan="1" colspan="1">0.640</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Metformin</td><td align="center" valign="top" rowspan="1" colspan="1">422 (2.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (5.4)</td><td align="center" valign="top" rowspan="1" colspan="1">405 (2.8)</td><td align="center" valign="top" rowspan="1" colspan="1">13.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.007</td><td align="center" valign="top" rowspan="1" colspan="1">5.4</td><td align="center" valign="top" rowspan="1" colspan="1">4.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.023</td><td align="center" valign="top" rowspan="1" colspan="1">0.790</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SGLT&#8208;2</td><td align="center" valign="top" rowspan="1" colspan="1">251 (1.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (5.0)</td><td align="center" valign="top" rowspan="1" colspan="1">235 (1.6)</td><td align="center" valign="top" rowspan="1" colspan="1">19.1</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">5.0</td><td align="center" valign="top" rowspan="1" colspan="1">4.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.028</td><td align="center" valign="top" rowspan="1" colspan="1">0.690</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DPP&#8208;4</td><td align="center" valign="top" rowspan="1" colspan="1">764 (5.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">48 (15.1)</td><td align="center" valign="top" rowspan="1" colspan="1">716 (5.0)</td><td align="center" valign="top" rowspan="1" colspan="1">34.1</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">15.1</td><td align="center" valign="top" rowspan="1" colspan="1">14.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.031</td><td align="center" valign="top" rowspan="1" colspan="1">0.690</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sulphonylureas</td><td align="center" valign="top" rowspan="1" colspan="1">414 (2.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (3.5)</td><td align="center" valign="top" rowspan="1" colspan="1">403 (2.8)</td><td align="center" valign="top" rowspan="1" colspan="1">4.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.473</td><td align="center" valign="top" rowspan="1" colspan="1">3.5</td><td align="center" valign="top" rowspan="1" colspan="1">2.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.085</td><td align="center" valign="top" rowspan="1" colspan="1">0.300</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Thiazolidinedione</td><td align="center" valign="top" rowspan="1" colspan="1">108 (0.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (0.9)</td><td align="center" valign="top" rowspan="1" colspan="1">105 (0.7)</td><td align="center" valign="top" rowspan="1" colspan="1">2.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.653</td><td align="center" valign="top" rowspan="1" colspan="1">0.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.000<xref rid="liv16132-note-0012" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.920</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Statins</td><td align="center" valign="top" rowspan="1" colspan="1">324 (2.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (2.5)</td><td align="center" valign="top" rowspan="1" colspan="1">316 (2.2)</td><td align="center" valign="top" rowspan="1" colspan="1">2.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.691</td><td align="center" valign="top" rowspan="1" colspan="1">2.5</td><td align="center" valign="top" rowspan="1" colspan="1">2.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.034</td><td align="center" valign="top" rowspan="1" colspan="1">0.660</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hepatic decompensation</td><td align="center" valign="top" rowspan="1" colspan="1">4717 (32.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">71 (22.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">4646 (32.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">22.1</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">22.4</td><td align="center" valign="top" rowspan="1" colspan="1">22.9</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.012</td><td align="center" valign="top" rowspan="1" colspan="1">0.890</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Ascites</td><td align="center" valign="top" rowspan="1" colspan="1">2820 (19.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (8.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">2793 (19.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">31.9</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">8.5</td><td align="center" valign="top" rowspan="1" colspan="1">8.9</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.014</td><td align="center" valign="top" rowspan="1" colspan="1">0.850</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hepatic encephalopathy</td><td align="center" valign="top" rowspan="1" colspan="1">2290 (15.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">40 (12.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">2250 (15.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">8.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.146</td><td align="center" valign="top" rowspan="1" colspan="1">12.6</td><td align="center" valign="top" rowspan="1" colspan="1">12.7</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.003</td><td align="center" valign="top" rowspan="1" colspan="1">0.960</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hepatorenal syndrome</td><td align="center" valign="top" rowspan="1" colspan="1">150 (1.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">150 (1.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">398.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.068</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0.5</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.100</td><td align="center" valign="top" rowspan="1" colspan="1">0.190</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">SBP</td><td align="center" valign="top" rowspan="1" colspan="1">366 (2.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (1.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">362 (2.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">8.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.157</td><td align="center" valign="top" rowspan="1" colspan="1">1.3</td><td align="center" valign="top" rowspan="1" colspan="1">1.7</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.033</td><td align="center" valign="top" rowspan="1" colspan="1">0.670</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Variceal bleeding</td><td align="center" valign="top" rowspan="1" colspan="1">700 (4.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (3.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">688 (4.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">4.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.413</td><td align="center" valign="top" rowspan="1" colspan="1">3.8</td><td align="center" valign="top" rowspan="1" colspan="1">3.9</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.005</td><td align="center" valign="top" rowspan="1" colspan="1">0.960</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hepatocellular carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">563 (3.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.3)</td><td align="center" valign="top" rowspan="1" colspan="1">562 (3.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">25.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.000<xref rid="liv16132-note-0012" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.960</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Liver transplant</td><td align="center" valign="top" rowspan="1" colspan="1">374 (2.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (1.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">370 (2.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">9.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.144</td><td align="center" valign="top" rowspan="1" colspan="1">1.3</td><td align="center" valign="top" rowspan="1" colspan="1">1.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.009</td><td align="center" valign="top" rowspan="1" colspan="1">0.980</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Portal Hypertension</td><td align="center" valign="top" rowspan="1" colspan="1">2345 (15.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">46 (14.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">2299 (16.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">4.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.488</td><td align="center" valign="top" rowspan="1" colspan="1">14.5</td><td align="center" valign="top" rowspan="1" colspan="1">12.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.056</td><td align="center" valign="top" rowspan="1" colspan="1">0.500</td></tr></tbody></table><table-wrap-foot id="liv16132-ntgp-0003"><fn id="liv16132-note-0008"><p>Abbreviations: AIDS, acquired immunodeficiency syndrome; DPP&#8208;4, dipeptidyl peptidase&#8208;4 inhibitors; GLP&#8208;1RA, glucagon&#8208;like peptide&#8208;1 receptor agonist; SBP, spontaneous bacterial peritonitis; SGLT&#8208;2, sodium&#8211;glucose cotransporter&#8208;2.</p></fn><fn id="liv16132-note-0009"><label>
<sup>a</sup>
</label><p>Pseudosample was created using the overlap weighting technique, ensuring that GLP&#8208;1RA initiation is independent of other clinicodemographic characteristics of the patients.</p></fn><fn id="liv16132-note-0010"><label>
<sup>b</sup>
</label><p>Absolute difference in means/proportions divided by pooled SD. The absolute value greater than 0.10 represented an imbalance between two study groups; smaller values indicate better balance.</p></fn><fn id="liv16132-note-0011"><label>
<sup>c</sup>
</label><p>Overlap weighted proportions and standardised differences calculated by using all patient demographics and medical history.</p></fn><fn id="liv16132-note-0012"><label>
<sup>d</sup>
</label><p>Overlapping weighting resulted in an exact balance for this variable.</p></fn></table-wrap-foot></table-wrap><p>The primary exposure variable was the initiation of GLP&#8208;1RAs, treated as a time&#8208;varying factor to accommodate the duration between the index diagnosis of ALD and the start date of GLP&#8208;1RA therapy. Accordingly, patients were categorised into the exposure group if GLP&#8208;1RAs were initiated before (1) the occurrence of an ALO event, (2) the end of enrolment in the insurance plan or (3) the conclusion of the study period. Conversely, patients who commenced GLP&#8208;1RA therapy after said events were classified as unexposed (Figure&#160;<xref rid="liv16132-fig-0002" ref-type="fig">2</xref>).</p><fig position="float" fig-type="FIGURE" id="liv16132-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Study design detailing time&#8208;varying modelling of glucagon&#8208;like peptide&#8208;1 receptor agonist (GLP&#8208;1RA) initiation status.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="LIV-45-0-g003.jpg"/></fig></sec><sec id="liv16132-sec-0010"><label>2.2</label><title>Outcome of Interest</title><p>The primary outcome of interest was ALO. ALO was defined as a composite measure of the first occurrence of hepatic decompensation, HCC, portal hypertension or liver transplantation [<xref rid="liv16132-bib-0010" ref-type="bibr">10</xref>]. Hepatic decompensation included ascites, hepatorenal syndrome, variceal bleeding, spontaneous bacterial peritonitis (SBP) and hepatic encephalopathy. These outcomes were determined by the record of two outpatient or one inpatient diagnosis identified through ICD&#8208;9/10 codes, as defined previously (Table&#160;<xref rid="liv16132-supitem-0001" ref-type="supplementary-material">S2</xref>) [<xref rid="liv16132-bib-0010" ref-type="bibr">10</xref>, <xref rid="liv16132-bib-0019" ref-type="bibr">19</xref>]. The secondary outcomes were the cause&#8208;specific incidence of each of the four individual components of the composite ALO. Patients with a baseline history of ALO at the time of their initial ALD diagnosis were included in the study, yet were not considered in the outcome analyses. For example, if a patient had no prior history of portal hypertension but did have a history of ascites before the index diagnosis of ALD, any subsequent record of ascites during follow&#8208;up was not considered an incident event and was excluded from outcome analyses. However, any record of portal hypertension during follow&#8208;up was included in both the primary and secondary composite outcomes, which was consistent with previous methodologies [<xref rid="liv16132-bib-0010" ref-type="bibr">10</xref>].</p></sec><sec id="liv16132-sec-0011"><label>2.3</label><title>Follow&#8208;Up Time</title><p>To examine primary outcomes, patients were followed from the date of initial diagnosis of ALD until the occurrence of the ALO event. For individuals who did not experience any ALO events, follow&#8208;up continued until either their enrolment in the insurance plan ended or until the conclusion of the study period, whichever came first. Similarly, in evaluating the secondary outcome, if a patient developed a single ALO before other events, the initial event was regarded as the primary focus and follow&#8208;up was extended only until the incidence of the initial ALO event [<xref rid="liv16132-bib-0010" ref-type="bibr">10</xref>].</p></sec><sec id="liv16132-sec-0012"><label>2.4</label><title>Statistical Analyses</title><p>Categorical variables were summarised with frequencies and percentages with comparisons made using either the chi&#8208;square or the Fisher exact test (<italic toggle="yes">&#967;</italic>
<sup>2</sup>). Continuous variables were expressed as medians with interquartile ranges (IQR) and analysed using either the Student's t&#8208;test or the Wilcoxon rank&#8208;sum test, as deemed suitable. Overlap propensity score weighting (OPSW) was employed to mitigate the confounding influence of baseline clinicodemographic characteristics on the clinical suitability of GLP&#8208;1RAs [<xref rid="liv16132-bib-0024" ref-type="bibr">24</xref>]. OPSW achieves precise balance across covariates included in the propensity score estimation via logistic regression, closely mimicking key aspects of randomised controlled trials such as statistical accuracy and covariate equilibrium [<xref rid="liv16132-bib-0025" ref-type="bibr">25</xref>]. Consequently, these attributes render OPSW superior to alternative weighting techniques such as inverse probability of treatment weighting [<xref rid="liv16132-bib-0024" ref-type="bibr">24</xref>, <xref rid="liv16132-bib-0025" ref-type="bibr">25</xref>]. The multivariable logistic regression models estimating propensity scores were adjusted for all clinicodemographic characteristics, including their first&#8208;order interactions, as covariates (Table&#160;<xref rid="liv16132-tbl-0001" ref-type="table">1</xref>).</p><p>Two methods were employed to assess the effectiveness of OPSW in addressing baseline differences between the GLP&#8208;1RAs and non&#8208;GLP&#8208;1RAs groups. In the initial approach, general overlap&#8208;weighted standardised differences were used to compare the two cohorts, with a difference of less than 0.1 indicating a negligible contrast in characteristics [<xref rid="liv16132-bib-0026" ref-type="bibr">26</xref>]. Subsequently, OPSW&#8208;based t&#8208;tests and <italic toggle="yes">&#967;</italic>
<sup>2</sup> were utilised to analyse the association of patient characteristics in the weighted sample with GLP&#8208;1RA exposure. Since the exposure was modelled as a time&#8208;varying factor, the cumulative incidence of ALO over a 3&#8208;year follow&#8208;up period was estimated using the method described by Simon and Makuch [<xref rid="liv16132-bib-0027" ref-type="bibr">27</xref>]. Cause&#8208;specific incidence rates for each group were calculated by dividing the number of outcome&#8208;specific events by the total person&#8208;years of follow&#8208;up. In turn, incidence rate ratio and absolute incidence rate differences for all outcomes were calculated in relation to GLP&#8208;1RAs status. The OPSW&#8208;based Poisson regression models were used to analyse the association of GLP&#8208;1RAs with outcomes to obtain adjusted risk estimates for each year of follow&#8208;up (at 1 to 3&#8201;years). All statistical analyses were performed using SAS 9.4 (SAS Institute); statistical significance was defined as a <italic toggle="yes">p</italic>&#8208;value of less than 0.05.</p></sec></sec><sec sec-type="results" id="liv16132-sec-0013"><label>3</label><title>Results</title><sec id="liv16132-sec-0014"><label>3.1</label><title>Baseline Characteristics</title><p>Among 14&#8201;730 patients, most individuals were male (<italic toggle="yes">n</italic>&#8201;=&#8201;9752, 66.2%) with a median age of 57 (IQR: 52&#8211;61) years. Most patients were enrolled with a preferred provider organisation (<italic toggle="yes">n</italic>&#8201;=&#8201;8224, 55.8%), followed by health maintenance organisations (HMO) (<italic toggle="yes">n</italic>&#8201;=&#8201;1916, 13.0%), comprehensive plans (<italic toggle="yes">n</italic>&#8201;=&#8201;802, 5.4%) and point of service plans (<italic toggle="yes">n</italic>&#8201;=&#8201;969, 6.6%) with the remainder enrolled in other benefit plans (<italic toggle="yes">n</italic>&#8201;=&#8201;2819, 19.1%). Over one&#8208;half of patients had a CCI score of 0 (<italic toggle="yes">n</italic>&#8201;=&#8201;8639, 58.6%), while a quarter had a CCI score of 1&#8211;2 (<italic toggle="yes">n</italic>&#8201;=&#8201;3595, 24.4%). There was a roughly equal distribution among nonfrail (<italic toggle="yes">n</italic>&#8201;=&#8201;6993, 47.5%) and prefrail (<italic toggle="yes">n</italic>&#8201;=&#8201;7021, 47.7%) patients, with a small subset of individuals who were categorised as frail (<italic toggle="yes">n</italic>&#8201;=&#8201;716, 4.9%).</p><p>Among other baseline clinical characteristics, 8.5% (1259) of patients had obesity, 8.3% (<italic toggle="yes">n</italic>&#8201;=&#8201;1220) suffered from congestive heart failure and 9.1% (<italic toggle="yes">n</italic>&#8201;=&#8201;1344) had renal disease. Overall, 32.0% (<italic toggle="yes">n</italic>&#8201;=&#8201;4717) of patients experienced hepatic decompensation, 15.9% (<italic toggle="yes">n</italic>&#8201;=&#8201;2345) had features of portal hypertension, 3.8% (<italic toggle="yes">n</italic>&#8201;=&#8201;563) had an incident development of an HCC and 2.5% (<italic toggle="yes">n</italic>&#8201;=&#8201;374) underwent liver transplantation. Overall, 2.2% (<italic toggle="yes">n</italic>&#8201;=&#8201;317) of patients were exposed to GLP&#8208;1RA use (Table&#160;<xref rid="liv16132-tbl-0001" ref-type="table">1</xref>).</p></sec><sec id="liv16132-sec-0015"><label>3.2</label><title>Characteristics Relative to <styled-content style="fixed-case" toggle="no">GLP</styled-content>&#8208;<styled-content style="fixed-case" toggle="no">1RA</styled-content> Exposure</title><p>Compared with non&#8208;GLP&#8208;1RA patients, individuals who were exposed to GLP&#8208;1RA were more likely to be female (50.2% vs. 33.4%), younger (56 vs. 58&#8201;years) and less likely to be enrolled with an HMO (9.5% vs. 13.1%) or be retirees (23.0% vs. 31.6%) (all <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). Furthermore, patients who started GLP&#8208;1RA had lower likelihood of claim&#8208;based frailty (3.2% vs. 4.9%; <italic toggle="yes">p</italic>&#8201;=&#8201;0.030); however, there was no difference relative to overall comorbidity burden based on CCI (<italic toggle="yes">p</italic>&#8201;=&#8201;0.183). Additionally, differences were noted among certain key baseline comorbidities whereby patients on GLP&#8208;1RA were less likely to have congestive heart failure (4.4% vs. 8.4%; <italic toggle="yes">p</italic>&#8201;=&#8201;0.012), renal disease (5.7% vs. 9.2%; <italic toggle="yes">p</italic>&#8201;=&#8201;0.031), yet be more likely to have obesity (16.4% vs. 8.4; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) or rheumatic disease (3.5% vs. 1.9%; <italic toggle="yes">p</italic>&#8201;=&#8201;0.048). Similarly, patients with GLP&#8208;1RA initiation had higher concurrent use of other antiglycaemic medications such as metformin (5.4% vs. 2.8%), sodium&#8211;glucose cotransporter&#8208;2 inhibitors (5.0% vs. 1.6%) and dipeptidyl peptidase&#8208;4 inhibitors (15.1 vs. 5.0) (all <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). Of note, patients taking GLP&#8208;1RA had a lower incidence of hepatic decompensation (22.4% vs. 32.2%) and HCC (0.3% vs. 3.0%) compared with individuals not taking GLP&#8208;1RA (both <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001); there was no association of GLP&#8208;1RA with the incidence of portal hypertension (14.5% vs. 16.0%; <italic toggle="yes">p</italic>&#8201;=&#8201;0.488) and liver transplantation (1.3% vs. 2.6%; <italic toggle="yes">p</italic>&#8201;=&#8201;0.144) (Table&#160;<xref rid="liv16132-tbl-0002" ref-type="table">2</xref>).</p></sec><sec id="liv16132-sec-0016"><label>3.3</label><title>OPSW</title><p>The median follow&#8208;up time for all patients was 42.2 (IQR: 17.8&#8211;84.0) months (GLP&#8208;1RA, 55.0 [IQR: 26.0&#8211;91.3] months vs. non&#8208;GLP&#8208;1RA, 42.0 [IQR: 17.5&#8211;83.8] months). On average, patients waited 5.5&#8201;months (standard deviation [SD]: &#177;3.8) after being diagnosed with ALD before starting GLP&#8208;1RA. Similarly, the median time from GLP&#8208;1RA exposure to the incidence of ALO was 14.0 (IQR: 6.6&#8211;27.8) months. After applying OPSW, all the clinicodemographic characteristics of patients who did and did not receive GLP&#8208;1RA were well balanced (Table&#160;<xref rid="liv16132-tbl-0001" ref-type="table">1</xref>). Of note, patients on GLP&#8208;1RA had a lower occurrence of composite ALO, with 46 events over 379 person&#8208;years versus 75 ALO events over 353 person&#8208;years in the unexposed group. The overall incidence of ALO was lower in the GLP&#8208;1RA cohort (GLP&#8208;1RA: 12.0%, 95%CI 9.0&#8211;16.0 vs. non&#8208;GLP&#8208;1RA: 21.0%, 95%CI 20.0&#8211;22.0) with an absolute incidence risk reduction of 9.0% (95%CI 3.0%&#8211;15.0%) associated with GLP&#8208;1RA (Figure&#160;<xref rid="liv16132-fig-0003" ref-type="fig">3a</xref>). On further stratification and cause&#8208;specific analyses, this association was primarily driven by a reduction in the incidence of hepatic decompensation among the different ALO components. Particularly, there was a 7.0% (95%CI 4.0&#8211;8.0) absolute reduction in the incidence of hepatic decompensation with an incidence rate of 8.0% (95%CI 6.0&#8211;12.0) in the GLP&#8208;1RA group versus 15.0% (95%CI 14.0&#8211;16.0) in the non&#8208;GLP&#8208;1RA group (Figure&#160;<xref rid="liv16132-fig-0003" ref-type="fig">3b</xref>). In contrast, there were no differences in incidence rates of portal hypertension, HCC and liver transplantation between the two cohorts. On Poisson regression, after accounting for other clinicodemographic characteristics, the adjusted incidence rate of ALO and hepatic decompensation among GLP&#8208;1RA initiation group remained lower at 0.57 (95%CI 0.39&#8211;0.82) and 0.56 (95%CI 0.36&#8211;0.86), respectively (Table&#160;<xref rid="liv16132-tbl-0003" ref-type="table">3</xref>).</p><fig position="float" fig-type="FIGURE" id="liv16132-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Overlapping weight&#8208;adjusted cumulative incidence of (A) adverse liver outcome and (B) hepatic decompensation by glucagon&#8208;like peptide&#8208;1 receptor agonists initiation status in adults with alcoholic liver disease and type 2 diabetes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="LIV-45-0-g002.jpg"/></fig><table-wrap position="float" id="liv16132-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Associations between glucagon&#8208;like peptide&#8208;1 receptor agonists initiation<xref rid="liv16132-note-0014" ref-type="table-fn">
<sup>a</sup>
</xref> and risk of adverse liver outcomes<xref rid="liv16132-note-0015" ref-type="table-fn">
<sup>b</sup>
</xref> in adults with alcoholic liver disease and type 2 diabetes.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Outcomes</th><th align="center" valign="bottom" rowspan="1" colspan="1">Number of events</th><th align="center" valign="bottom" rowspan="1" colspan="1">Person&#8208;years</th><th align="center" valign="bottom" rowspan="1" colspan="1">Incidence rates per person&#8208;years (95%CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Absolute incidence rate difference per person&#8208;years (95%CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Incidence rate ratio (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Adjusted incidence rate (95%CI)<xref rid="liv16132-note-0016" ref-type="table-fn">
<sup>c</sup>
</xref>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Adverse liver outcomes</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No GLP&#8208;1RA</td><td align="center" valign="top" rowspan="1" colspan="1">75</td><td align="center" valign="top" rowspan="1" colspan="1">353</td><td align="center" valign="top" rowspan="1" colspan="1">0.21 (0.20&#8211;0.22)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">Ref.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GLP&#8208;1RA</td><td align="center" valign="top" rowspan="1" colspan="1">46</td><td align="center" valign="top" rowspan="1" colspan="1">379</td><td align="center" valign="top" rowspan="1" colspan="1">0.12 (0.09&#8211;0.16)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.09 (&#8722;0.15 to &#8722;0.03)</td><td align="center" valign="top" rowspan="1" colspan="1">0.55 (0.38&#8211;0.80)</td><td align="center" valign="top" rowspan="1" colspan="1">0.57 (0.39&#8211;0.82)<xref rid="liv16132-note-0017" ref-type="table-fn">
<sup>d</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hepatic decompensation</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No GLP&#8208;1RA</td><td align="center" valign="top" rowspan="1" colspan="1">57</td><td align="center" valign="top" rowspan="1" colspan="1">381</td><td align="center" valign="top" rowspan="1" colspan="1">0.15 (0.14&#8211;0.16)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">Ref.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GLP&#8208;1RA</td><td align="center" valign="top" rowspan="1" colspan="1">33</td><td align="center" valign="top" rowspan="1" colspan="1">400</td><td align="center" valign="top" rowspan="1" colspan="1">0.08 (0.06&#8211;0.12)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.07 (&#8722;0.08 to &#8722;0.04)</td><td align="center" valign="top" rowspan="1" colspan="1">0.55 (0.42&#8211;0.74)</td><td align="center" valign="top" rowspan="1" colspan="1">0.56 (0.36&#8211;0.86)<xref rid="liv16132-note-0017" ref-type="table-fn">
<sup>d</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hepatocellular carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No GLP&#8208;1RA</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">429</td><td align="center" valign="top" rowspan="1" colspan="1">0.02 (0.02&#8211;0.03)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">Ref.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GLP&#8208;1RA</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">427</td><td align="center" valign="top" rowspan="1" colspan="1">0.01 (0.00&#8211;0.05)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.02 (&#8722;0.02 to 0.02)</td><td align="center" valign="top" rowspan="1" colspan="1">0.21 (0.05&#8211;1.82)</td><td align="center" valign="top" rowspan="1" colspan="1">0.32 (0.06&#8211;1.63)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Liver transplant</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No GLP&#8208;1RA</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">433</td><td align="center" valign="top" rowspan="1" colspan="1">0.01 (0.008&#8211;0.012)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">Ref.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GLP&#8208;1RA</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">428</td><td align="center" valign="top" rowspan="1" colspan="1">0.002 (0.001&#8211;0.009)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.007 (&#8722;0.008 to &#8722;0.004)</td><td align="center" valign="top" rowspan="1" colspan="1">0.22 (0.11&#8211;0.71)</td><td align="center" valign="top" rowspan="1" colspan="1">0.57 (0.60&#8211;5.49)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Portal Hypertension</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No GLP&#8208;1RA</td><td align="center" valign="top" rowspan="1" colspan="1">35</td><td align="center" valign="top" rowspan="1" colspan="1">398</td><td align="center" valign="top" rowspan="1" colspan="1">0.09 (0.08&#8211;0.10)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">Ref.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GLP&#8208;1RA</td><td align="center" valign="top" rowspan="1" colspan="1">29</td><td align="center" valign="top" rowspan="1" colspan="1">400</td><td align="center" valign="top" rowspan="1" colspan="1">0.07 (0.05&#8211;0.11)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.02 (&#8722;0.03 to 0.01)</td><td align="center" valign="top" rowspan="1" colspan="1">0.81 (0.61&#8211;1.10)</td><td align="center" valign="top" rowspan="1" colspan="1">0.76 (0.46&#8211;1.24)</td></tr></tbody></table><table-wrap-foot id="liv16132-ntgp-0004"><fn id="liv16132-note-0013"><p>Abbreviations: CI, confidence interval, GLP&#8208;1RA: glucagon&#8208;like peptide 1 receptor agonists.</p></fn><fn id="liv16132-note-0014"><label>
<sup>a</sup>
</label><p>Glucagon&#8208;like peptide&#8208;1 receptor agonists initiation status was modelled as a time&#8208;dependent covariate.</p></fn><fn id="liv16132-note-0015"><label>
<sup>b</sup>
</label><p>Adverse liver outcomes were defined as (1) hepatic decompensation (ascites, hepatic encephalopathy, hepatorenal syndrome, spontaneous bacterial peritonitis and variceal bleeding), (2) hepatocellular carcinoma, (3) liver transplant and (4) portal hypertension.</p></fn><fn id="liv16132-note-0016"><label>
<sup>c</sup>
</label><p>Adjusted using overlapping weights estimated using age, sex, region of residence, type of health insurance, year of diagnosis, employment status, history of smoking, obesity, dyslipidaemia, hypertension, Charlson Comorbidity Index, claims&#8208;based frailty index, metformin, SGLT&#8208;2, DPP&#8208;4, sulphonylureas, thiazolidinediones and statins.</p></fn><fn id="liv16132-note-0017"><label>
<sup>d</sup>
</label><p>
<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05.</p></fn></table-wrap-foot></table-wrap></sec><sec id="liv16132-sec-0017"><label>3.4</label><title>Sensitivity Analyses</title><p>After stratifying patients by baseline liver compensation status, there was an equal benefit of GLP&#8208;1RA relative to the reduced incidence of overall ALO (baseline compensated ALD: adjusted IR of ALO: 0.63, 95%CI 0.40&#8211;0.99; <italic toggle="yes">p</italic>&#8201;=&#8201;0.043 vs. baseline decompensated ALD: adjusted IR of ALO: 0.42, 95%CI 0.40&#8211;0.45; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) (Table&#160;<xref rid="liv16132-supitem-0001" ref-type="supplementary-material">S3</xref>). Two additional sensitivity analyses performed using inverse probability of treatment weighting with redefinitions of the primary and secondary outcomes as events occurring 6&#8201;months after the index date demonstrated similar findings.</p></sec></sec><sec sec-type="discussion" id="liv16132-sec-0018"><label>4</label><title>Discussion</title><p>Over the past decade, the primary cause of death due to chronic liver disease has shifted from viral hepatitis to fatty liver disease [<xref rid="liv16132-bib-0028" ref-type="bibr">28</xref>]. Consequently, there is a growing emphasis on understanding fatty liver such as ALD and MASH to address the rising liver&#8208;related health burden [<xref rid="liv16132-bib-0029" ref-type="bibr">29</xref>, <xref rid="liv16132-bib-0030" ref-type="bibr">30</xref>]. Despite efforts to regulate alcohol access and reduce alcohol abuse, ALD continues to be one of the leading causes of liver&#8208;related illness and mortality [<xref rid="liv16132-bib-0029" ref-type="bibr">29</xref>, <xref rid="liv16132-bib-0030" ref-type="bibr">30</xref>, <xref rid="liv16132-bib-0031" ref-type="bibr">31</xref>]. In fact, over half of deaths from alcohol&#8208;related causes are due to liver disease with the associated mortality nearly doubling each year [<xref rid="liv16132-bib-0003" ref-type="bibr">3</xref>, <xref rid="liv16132-bib-0028" ref-type="bibr">28</xref>]. Traditionally, medications such as acamprosate and naltrexone are approved for managing alcohol use disorder yet these drugs do not offer any metabolic benefits for concurrent alcohol&#8208;induced dysfunction [<xref rid="liv16132-bib-0012" ref-type="bibr">12</xref>, <xref rid="liv16132-bib-0032" ref-type="bibr">32</xref>]. Of note, GLP&#8208;1RAs&#8212;which are well recognised in the management of diabetes mellitus through improved glycaemic control&#8212;have been suggested to help create an aversion to alcohol consumption [<xref rid="liv16132-bib-0012" ref-type="bibr">12</xref>]. Nonetheless, the impact of GLP&#8208;1RA intake on liver outcomes among patients with ALD had not been investigated. Therefore, the current study was important as it defined the association of GLP&#8208;1RA initiation with the incidence of ALO among patients with T2DM who were newly diagnosed with ALD. Notably, patients with GLP&#8208;1RA initiation after an index diagnosis of ALD had a lower overall incidence of ALO, particularly hepatic decompensation. Interestingly, on a stratified analysis, the benefit of GLP&#8208;1RA on composite ALO remained consistent across patients with or without baseline liver compensation.</p><p>There is evidence that alcohol&#8208;associated fatty liver disease, particularly when accompanied by advanced fibrosis, is an independent predictor of both liver&#8208;specific and all&#8208;cause mortality [<xref rid="liv16132-bib-0033" ref-type="bibr">33</xref>]. Diabetes, which is disproportionately common among patients with ALD, is another known risk factor that can contribute to liver&#8208;associated complications [<xref rid="liv16132-bib-0034" ref-type="bibr">34</xref>]. To this end, antidiabetic drugs such as metformin, thiazolidinediones and GLP&#8208;1RA can reverse steatosis and improve liver function [<xref rid="liv16132-bib-0035" ref-type="bibr">35</xref>]. In fact, previous studies have demonstrated that GLP&#8208;1RAs, particularly semaglutide, were associated with the resolution of steatohepatitis in patients with T2DM [<xref rid="liv16132-bib-0036" ref-type="bibr">36</xref>, <xref rid="liv16132-bib-0037" ref-type="bibr">37</xref>]. This effect may result from reduced insulin resistance and weight loss, which in turn can improve overall metabolic function and reduce the liver fat content [<xref rid="liv16132-bib-0036" ref-type="bibr">36</xref>]. These desirable effects may explain findings in the current study, which demonstrated that initiation of GLP&#8208;1RA treatment reduced the incidence rate of ALO per person&#8208;years by 9% among patients with ALD. Interestingly, after adjusting for confounding variables in multivariable analysis, GLP&#8208;1RA remained independently associated with a 43% reduced incidence of composite ALO.</p><p>Managing ALO may differ based on different baseline liver compensation or decompensation status [<xref rid="liv16132-bib-0010" ref-type="bibr">10</xref>]. Prior evidence has suggested that GLP&#8208;1RA may be superior to other antidiabetic medications in reducing the risk of HCC and hepatic decompensation [<xref rid="liv16132-bib-0038" ref-type="bibr">38</xref>]. Similarly, among patients with T2DM who have been diagnosed with MASH, GLP&#8208;1RA has been suggested to be associated with improved liver&#8208;related outcomes [<xref rid="liv16132-bib-0010" ref-type="bibr">10</xref>]. In the present study, the beneficial effects of GLP&#8208;1RA were consistent across patients with incidence of hepatic decompensation (22.4% vs. 32.2%) and HCC (0.3% vs. 3.9%) diagnosis in the unweighted models of patients newly diagnosed with ALD. Importantly, after OPSW&#8208;based analysis, the effects of GLP&#8208;1RA on ALO were demonstrated to be primarily mediated through a marked (44%) reduction in the incidence of hepatic decompensation. Given that GLP&#8208;1RAs are primarily excreted unchanged through the kidneys, the benefits of the drug may be mainly among patients with compensated liver disease [<xref rid="liv16132-bib-0039" ref-type="bibr">39</xref>]. To address this question, a separate analysis was conducted among patients with baseline decompensation to assess the impact of GLP&#8208;1RA initiation on ALO. This analysis demonstrated that patients with already diagnosed liver decompensation experienced the same benefits of taking GLP&#8208;1RA as individuals with compensated liver disease. These findings aligned with a previous study in which patients with baseline decompensation associated with MASH had equally favourable effects from initiation of GLP&#8208;1RA [<xref rid="liv16132-bib-0010" ref-type="bibr">10</xref>]. There is prior evidence that GLP&#8208;1RA has the potential to enhance and possibly reverse diabetic nephropathy by affecting the renin&#8211;angiotensin&#8211;aldosterone axis (RAAS) [<xref rid="liv16132-bib-0040" ref-type="bibr">40</xref>]. It is worth noting that there is a common underlying mechanism associated with hepatorenal syndrome, and enhanced renal function may be a reason for similar benefits of GLP&#8208;1RA among patients with decompensated liver disease [<xref rid="liv16132-bib-0041" ref-type="bibr">41</xref>].</p><p>While the benefits may extend beyond managing T2DM alone, utilisation of GLP&#8208;1RA remains relatively low [<xref rid="liv16132-bib-0042" ref-type="bibr">42</xref>]. Previously reported usage data ranged from as low as 9% to 15% among patients with diabetes [<xref rid="liv16132-bib-0010" ref-type="bibr">10</xref>, <xref rid="liv16132-bib-0043" ref-type="bibr">43</xref>]. In the current study, only about 3% of patients initiated GLP&#8208;1RA treatment, likely due to the inclusion of patients with T2DM and concurrent ALD. The underuse of GLP&#8208;1RA can be multifaceted and may include factors such as therapeutic inertia among clinicians, patients' concerns about adverse effects and the mode of delivery [<xref rid="liv16132-bib-0044" ref-type="bibr">44</xref>, <xref rid="liv16132-bib-0045" ref-type="bibr">45</xref>]. Additionally, disparities in care have been noted with patients from higher socioeconomic backgrounds being more likely to receive modern antidiabetic treatments, including GLP&#8208;1RA [<xref rid="liv16132-bib-0043" ref-type="bibr">43</xref>]. Similarly, rising costs can be another contributing factor to low initiation rates of GLP&#8208;1RA [<xref rid="liv16132-bib-0046" ref-type="bibr">46</xref>]. According to a report by Sumarsono et&#160;al., GLP&#8208;1RAs are the second costliest antiglycaemic medication with a notable&#160;135% cost increase over the last 5&#8201;years [<xref rid="liv16132-bib-0046" ref-type="bibr">46</xref>]. Additionally, the Patient Protection and Affordable Care Act is expected to increase the cost burden on patients and private insurers may also shift cost shares [<xref rid="liv16132-bib-0047" ref-type="bibr">47</xref>]. Consequently, rising treatment expenses can place patients at risk of &#8216;financial toxicity&#8217;, which in turn can reduce preference for GLP&#8208;1RA [<xref rid="liv16132-bib-0047" ref-type="bibr">47</xref>, <xref rid="liv16132-bib-0048" ref-type="bibr">48</xref>]. Recently, following increased attention to the wide&#8208;ranging benefits of GLP&#8208;1RA, the FDA approved this class of drugs for additional indications, including weight management and the secondary prevention of cardiovascular events [<xref rid="liv16132-bib-0042" ref-type="bibr">42</xref>]. Data from the current study suggest that there may be additional benefits of GLP&#8208;1RA for patients with liver disease. Therefore, healthcare organisations and policymakers should focus on improving access to this class of drugs for patients with diabetes.</p><p>The findings of the current study should be interpreted considering certain limitations. The use of a retrospective administrative database may be prone to inaccurate data input and missing values. The IBM MarketSdcan database included only individuals with employer&#8208;sponsored health insurance in the United States, which may not represent other populations, such as uninsured individuals or those covered by government&#8208;sponsored health plans like Medicare or Medicaid [<xref rid="liv16132-bib-0016" ref-type="bibr">16</xref>]. Additionally, data collection relied on convenience sampling, which may limit the generalisability of the results. Since ICD and national drug codes were used to select the patient cohort, exposure of interest and outcomes, there was a risk of misclassification bias and residual confounding attributable to potential coding errors [<xref rid="liv16132-bib-0049" ref-type="bibr">49</xref>]. This was an observational study that only reported associations and could not ascertain causation. Nonetheless, the causal inference approach using overlap weighting alleviated confounding by indication [<xref rid="liv16132-bib-0010" ref-type="bibr">10</xref>]. Moreover, GLP&#8208;1RA was modelled as a time&#8208;varying variable to address immortal time bias. Approximately one&#8208;third of patients prescribed GLP&#8208;1RA fail to complete treatment [<xref rid="liv16132-bib-0050" ref-type="bibr">50</xref>]. To this point, the current study was unable to ascertain treatment completion rates, potentially limiting the study of the long&#8208;term benefits of GLP&#8208;1RA therapy. However, the focus of our investigation primarily centred on a 3&#8208;year follow&#8208;up period, which helped mitigate this limitation. Furthermore, due to the limited number of variables, granular assessment of patient&#8208;level factors (e.g., race/ethnicity) or severity of comorbidities that may drive the effects of GLP&#8208;1RA could not be assessed. Despite these limitations, the study provides valuable insight into the impact that GLP&#8208;1RA may have on patients with concurrent liver disease, which otherwise would be challenging to study in randomised controlled trials.</p><p>In conclusion, GLP&#8208;1RA may potentially mitigate the risk of ALO, particularly hepatic decompensation, among patients with ALD and concurrent T2DM. As such, these medications may be an effective therapeutic tool among these patients. Future trials are needed to further investigate the role of GLP&#8208;1RA among patients with liver disease.</p></sec><sec sec-type="COI-statement" id="liv16132-sec-0020"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec id="liv16132-sec-0023"><title>Disclaimer</title><p>The authors have nothing to report.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="liv16132-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Data S1.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="LIV-45-0-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="liv16132-sec-0019"><title>Acknowledgements</title><p>The authors have nothing to report.</p></ack><sec sec-type="data-availability" id="liv16132-sec-0022"><title>Data Availability Statement</title><p>The data for this study were obtained from the IBM Marketscan database. There are restrictions to the availability of these data, which is used under licence for this study. Data can be accessed with permission from the IBM Marketscan Commercial Database.</p></sec><ref-list content-type="cited-references" id="liv16132-bibl-0001"><title>References</title><ref id="liv16132-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="liv16132-cit-0001"><string-name name-style="western"><given-names>A. K.</given-names><surname>Singal</surname></string-name> and <string-name name-style="western"><given-names>P.</given-names><surname>Mathurin</surname></string-name>, &#8220;<article-title>Diagnosis and Treatment of Alcohol&#8208;Associated Liver Disease: A Review</article-title>,&#8221; <source>Journal of the American Medical Association</source><volume>326</volume>, no. <issue>2</issue> (<year>2021</year>): <fpage>165</fpage>, <pub-id pub-id-type="doi">10.1001/jama.2021.7683</pub-id>.<pub-id pub-id-type="pmid">34255003</pub-id></mixed-citation></ref><ref id="liv16132-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="liv16132-cit-0002"><string-name name-style="western"><given-names>A. G. L.</given-names><surname>Vannier</surname></string-name>, <string-name name-style="western"><given-names>J. E. S.</given-names><surname>Shay</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Fomin</surname></string-name>, et&#160;al., &#8220;<article-title>Incidence and Progression of Alcohol&#8208;Associated Liver Disease After Medical Therapy for Alcohol Use Disorder</article-title>,&#8221; <source>Journal of the American Medical Association Network Open</source><volume>5</volume>, no. <issue>5</issue> (<year>2022</year>): <elocation-id>e2213014</elocation-id>, <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.13014</pub-id>.<pub-id pub-id-type="pmcid">PMC9123494</pub-id><pub-id pub-id-type="pmid">35594048</pub-id></mixed-citation></ref><ref id="liv16132-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="liv16132-cit-0003"><string-name name-style="western"><given-names>S.</given-names><surname>Spillane</surname></string-name>, <string-name name-style="western"><given-names>M. S.</given-names><surname>Shiels</surname></string-name>, <string-name name-style="western"><given-names>A. F.</given-names><surname>Best</surname></string-name>, et&#160;al., &#8220;<article-title>Trends in Alcohol&#8208;Induced Deaths in the United States, 2000&#8208;2016</article-title>,&#8221; <source>Journal of the American Medical Association Network Open</source><volume>3</volume>, no. <issue>2</issue> (<year>2020</year>): <elocation-id>e1921451</elocation-id>, <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.21451</pub-id>.<pub-id pub-id-type="pmcid">PMC7043198</pub-id><pub-id pub-id-type="pmid">32083687</pub-id></mixed-citation></ref><ref id="liv16132-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="liv16132-cit-0004"><string-name name-style="western"><given-names>R.</given-names><surname>Rubin</surname></string-name>, &#8220;<article-title>Alcohol&#8208;Related Diseases Increased as Some People Drank More During the COVID&#8208;19 Pandemic</article-title>,&#8221; <source>Journal of the American Medical Association</source><volume>326</volume>, no. <issue>3</issue> (<year>2021</year>): <fpage>209</fpage>&#8211;<lpage>211</lpage>, <pub-id pub-id-type="doi">10.1001/jama.2021.10626</pub-id>.<pub-id pub-id-type="pmid">34190978</pub-id></mixed-citation></ref><ref id="liv16132-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="liv16132-cit-0005"><string-name name-style="western"><given-names>S. M.</given-names><surname>Rutledge</surname></string-name>, <string-name name-style="western"><given-names>T. D.</given-names><surname>Schiano</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Florman</surname></string-name>, and <string-name name-style="western"><given-names>G. Y.</given-names><surname>Im</surname></string-name>, &#8220;<article-title>COVID&#8208;19 Aftershocks on Alcohol&#8208;Associated Liver Disease: An Early Cross&#8208;Sectional Report From the U.S. Epicenter</article-title>,&#8221; <source>Hepatology Communications</source><volume>5</volume>, no. <issue>7</issue> (<year>2021</year>): <fpage>1151</fpage>&#8211;<lpage>1155</lpage>, <pub-id pub-id-type="doi">10.1002/hep4.1706</pub-id>.<pub-id pub-id-type="pmid">34533000</pub-id><pub-id pub-id-type="pmcid">PMC8013370</pub-id></mixed-citation></ref><ref id="liv16132-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="liv16132-cit-0006"><string-name name-style="western"><given-names>Z. M.</given-names><surname>Younossi</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Golabi</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>de Avila</surname></string-name>, et&#160;al., &#8220;<article-title>The Global Epidemiology of NAFLD and NASH in Patients With Type 2 Diabetes: A Systematic Review and Meta&#8208;Analysis</article-title>,&#8221; <source>Journal of Hepatology</source><volume>71</volume>, no. <issue>4</issue> (<year>2019</year>): <fpage>793</fpage>&#8211;<lpage>801</lpage>, <pub-id pub-id-type="doi">10.1016/j.jhep.2019.06.021</pub-id>.<pub-id pub-id-type="pmid">31279902</pub-id></mixed-citation></ref><ref id="liv16132-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="liv16132-cit-0007"><string-name name-style="western"><given-names>A. Y.</given-names><surname>Xiao</surname></string-name>, <string-name name-style="western"><given-names>M. L. Y.</given-names><surname>Tan</surname></string-name>, <string-name name-style="western"><given-names>L. M.</given-names><surname>Wu</surname></string-name>, et&#160;al., &#8220;<article-title>Global Incidence and Mortality of Pancreatic Diseases: A Systematic Review, Meta&#8208;Analysis, and Meta&#8208;Regression of Population&#8208;Based Cohort Studies</article-title>,&#8221; <source>Lancet Gastroenterology &amp; Hepatology</source><volume>1</volume>, no. <issue>1</issue> (<year>2016</year>): <fpage>45</fpage>&#8211;<lpage>55</lpage>, <pub-id pub-id-type="doi">10.1016/S2468-1253(16)30004-8</pub-id>.<pub-id pub-id-type="pmid">28404111</pub-id></mixed-citation></ref><ref id="liv16132-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="liv16132-cit-0008"><string-name name-style="western"><given-names>A.</given-names><surname>van de Wiel</surname></string-name>, &#8220;<article-title>Diabetes Mellitus and Alcohol</article-title>,&#8221; <source>Diabetes/Metabolism Research and Reviews</source><volume>20</volume>, no. <issue>4</issue> (<year>2004</year>): <fpage>263</fpage>&#8211;<lpage>267</lpage>, <pub-id pub-id-type="doi">10.1002/dmrr.492</pub-id>.<pub-id pub-id-type="pmid">15250029</pub-id></mixed-citation></ref><ref id="liv16132-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="liv16132-cit-0009"><string-name name-style="western"><given-names>W.</given-names><surname>Dunn</surname></string-name> and <string-name name-style="western"><given-names>V. H.</given-names><surname>Shah</surname></string-name>, &#8220;<article-title>Pathogenesis of Alcoholic Liver Disease</article-title>,&#8221; <source>Clinics in Liver Disease</source><volume>20</volume>, no. <issue>3</issue> (<year>2016</year>): <fpage>445</fpage>&#8211;<lpage>456</lpage>, <pub-id pub-id-type="doi">10.1016/j.cld.2016.02.004</pub-id>.<pub-id pub-id-type="pmid">27373608</pub-id><pub-id pub-id-type="pmcid">PMC4933837</pub-id></mixed-citation></ref><ref id="liv16132-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="liv16132-cit-0010"><string-name name-style="western"><given-names>M. I.</given-names><surname>Elsaid</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>S. A.</given-names><surname>Firkins</surname></string-name>, et&#160;al., &#8220;<article-title>Impacts of Glucagon&#8208;Like Peptide&#8208;1 Receptor Agonists on the Risk of Adverse Liver Outcomes in Patients With Metabolic Dysfunction&#8208;Associated Steatotic Liver Disease Cirrhosis and Type 2 Diabetes</article-title>,&#8221; <source>Alimentary Pharmacology &amp; Therapeutics</source><volume>59</volume>, no. <issue>9</issue> (<year>2024</year>): <fpage>1096</fpage>&#8211;<lpage>1110</lpage>, <pub-id pub-id-type="doi">10.1111/apt.17925</pub-id>.<pub-id pub-id-type="pmid">38538967</pub-id></mixed-citation></ref><ref id="liv16132-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="liv16132-cit-0011"><string-name name-style="western"><given-names>M.</given-names><surname>Decraecker</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Dutartre</surname></string-name>, <string-name name-style="western"><given-names>J. B.</given-names><surname>Hiriart</surname></string-name>, et&#160;al., &#8220;<article-title>Long&#8208;Term Prognosis of Patients With Alcohol&#8208;Related Liver Disease or Non&#8208;alcoholic Fatty Liver Disease According to Metabolic Syndrome or Alcohol Use</article-title>,&#8221; <source>Liver International</source><volume>42</volume>, no. <issue>2</issue> (<year>2022</year>): <fpage>350</fpage>&#8211;<lpage>362</lpage>, <pub-id pub-id-type="doi">10.1111/liv.15081</pub-id>.<pub-id pub-id-type="pmid">34679242</pub-id></mixed-citation></ref><ref id="liv16132-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="liv16132-cit-0012"><string-name name-style="western"><given-names>F.</given-names><surname>Quddos</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Hubshman</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Tegge</surname></string-name>, et&#160;al., &#8220;<article-title>Semaglutide and Tirzepatide Reduce Alcohol Consumption in Individuals With Obesity</article-title>,&#8221; <source>Scientific Reports</source><volume>13</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>20998</fpage>, <pub-id pub-id-type="doi">10.1038/s41598-023-48267-2</pub-id>.<pub-id pub-id-type="pmid">38017205</pub-id><pub-id pub-id-type="pmcid">PMC10684505</pub-id></mixed-citation></ref><ref id="liv16132-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="liv16132-cit-0013"><string-name name-style="western"><given-names>C.</given-names><surname>Patel Chavez</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Cusi</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Kadiyala</surname></string-name>, &#8220;<article-title>The Emerging Role of Glucagon&#8208;Like Peptide&#8208;1 Receptor Agonists for the Management of NAFLD</article-title>,&#8221; <source>Journal of Clinical Endocrinology and Metabolism</source><volume>107</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>29</fpage>&#8211;<lpage>38</lpage>, <pub-id pub-id-type="doi">10.1210/clinem/dgab578</pub-id>.<pub-id pub-id-type="pmid">34406410</pub-id><pub-id pub-id-type="pmcid">PMC8684453</pub-id></mixed-citation></ref><ref id="liv16132-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="liv16132-cit-0014"><string-name name-style="western"><given-names>C.</given-names><surname>Luna&#8208;Marco</surname></string-name>, <string-name name-style="western"><given-names>A. M.</given-names><surname>de Mara&#241;on</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Hermo&#8208;Argibay</surname></string-name>, et&#160;al., &#8220;<article-title>Effects of GLP&#8208;1 Receptor Agonists on Mitochondrial Function, Inflammatory Markers and Leukocyte&#8208;Endothelium Interactions in Type 2 Diabetes</article-title>,&#8221; <source>Redox Biology</source><volume>66</volume> (<year>2023</year>): <elocation-id>102849</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.redox.2023.102849</pub-id>.<pub-id pub-id-type="pmid">37591012</pub-id><pub-id pub-id-type="pmcid">PMC10457591</pub-id></mixed-citation></ref><ref id="liv16132-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="liv16132-cit-0015"><string-name name-style="western"><given-names>T. G.</given-names><surname>Simon</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Patorno</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Schneeweiss</surname></string-name>, &#8220;<article-title>Glucagon&#8208;Like Peptide&#8208;1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes</article-title>,&#8221; <source>Clinical Gastroenterology and Hepatology</source><volume>20</volume>, no. <issue>6</issue> (<year>2022</year>): <fpage>1382</fpage>&#8211;<lpage>1393.e19</lpage>, <pub-id pub-id-type="doi">10.1016/j.cgh.2021.07.010</pub-id>.<pub-id pub-id-type="pmid">34256144</pub-id><pub-id pub-id-type="pmcid">PMC8743301</pub-id></mixed-citation></ref><ref id="liv16132-bib-0016"><label>16</label><mixed-citation publication-type="book" id="liv16132-cit-0016"><string-name name-style="western"><given-names>A. M.</given-names><surname>Butler</surname></string-name>, <string-name name-style="western"><given-names>K. B.</given-names><surname>Nickel</surname></string-name>, <string-name name-style="western"><given-names>R. A.</given-names><surname>Overman</surname></string-name>, and <string-name name-style="western"><given-names>M. A.</given-names><surname>Brookhart</surname></string-name>, &#8220;<part-title>IBM MarketScan Research Databases</part-title>,&#8221; in <source>Databases for Pharmacoepidemiological Research</source>, eds. <person-group person-group-type="editor"><string-name name-style="western"><given-names>M.</given-names><surname>Sturkenboom</surname></string-name></person-group> and <person-group person-group-type="editor"><string-name name-style="western"><given-names>T.</given-names><surname>Schink</surname></string-name></person-group> (<publisher-name>Springer International Publishing</publisher-name>, <year>2021</year>), <fpage>243</fpage>&#8211;<lpage>251</lpage>, <pub-id pub-id-type="doi">10.1007/978-3-030-51455-6_20</pub-id>.</mixed-citation></ref><ref id="liv16132-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="liv16132-cit-0017"><string-name name-style="western"><given-names>M.</given-names><surname>Khalil</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Woldesenbet</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Munir</surname></string-name>, et&#160;al., &#8220;<article-title>Healthcare Utilization and Expenditures Among Patients With Venous Thromboembolism Following Gastrointestinal Cancer Surgery</article-title>,&#8221; <source>Journal of Gastrointestinal Surgery</source><volume>28</volume>, no. <issue>7</issue> (<year>2024</year>): <fpage>1151</fpage>&#8211;<lpage>1157</lpage>, <pub-id pub-id-type="doi">10.1016/j.gassur.2024.05.012</pub-id>.<pub-id pub-id-type="pmid">38762336</pub-id></mixed-citation></ref><ref id="liv16132-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="liv16132-cit-0018"><string-name name-style="western"><given-names>A.</given-names><surname>Paro</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Hyer</surname></string-name>, <string-name name-style="western"><given-names>C. F.</given-names><surname>Shaikh</surname></string-name>, and <string-name name-style="western"><given-names>T. M.</given-names><surname>Pawlik</surname></string-name>, &#8220;<article-title>Financial Impact of out&#8208;Of&#8208;Pocket Costs Among Patients Undergoing Resection for Colorectal Carcinoma</article-title>,&#8221; <source>Annals of Surgical Oncology</source><volume>29</volume>, no. <issue>9</issue> (<year>2022</year>): <fpage>5387</fpage>&#8211;<lpage>5397</lpage>, <pub-id pub-id-type="doi">10.1245/s10434-022-11755-2</pub-id>.<pub-id pub-id-type="pmid">35430665</pub-id><pub-id pub-id-type="pmcid">PMC9013274</pub-id></mixed-citation></ref><ref id="liv16132-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="liv16132-cit-0019"><string-name name-style="western"><given-names>D.</given-names><surname>Goldberg</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Lewis</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Halpern</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Weiner</surname></string-name>, and <string-name name-style="western"><given-names>V.</given-names><surname>Lo Re</surname>, <suffix>3rd</suffix></string-name>, &#8220;<article-title>Validation of Three Coding Algorithms to Identify Patients With End&#8208;Stage Liver Disease in an Administrative Database</article-title>,&#8221; <source>Pharmacoepidemiology and Drug Safety</source><volume>21</volume>, no. <issue>7</issue> (<year>2012</year>): <fpage>765</fpage>&#8211;<lpage>769</lpage>, <pub-id pub-id-type="doi">10.1002/pds.3290</pub-id>.<pub-id pub-id-type="pmid">22674685</pub-id><pub-id pub-id-type="pmcid">PMC4267226</pub-id></mixed-citation></ref><ref id="liv16132-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="liv16132-cit-0020"><string-name name-style="western"><given-names>H.</given-names><surname>Quan</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>C. M.</given-names><surname>Couris</surname></string-name>, et&#160;al., &#8220;<article-title>Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries</article-title>,&#8221; <source>American Journal of Epidemiology</source><volume>173</volume>, no. <issue>6</issue> (<year>2011</year>): <fpage>676</fpage>&#8211;<lpage>682</lpage>, <pub-id pub-id-type="doi">10.1093/aje/kwq433</pub-id>.<pub-id pub-id-type="pmid">21330339</pub-id></mixed-citation></ref><ref id="liv16132-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="liv16132-cit-0021"><string-name name-style="western"><given-names>Y. Q.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Gou</surname></string-name>, <string-name name-style="western"><given-names>Y. S.</given-names><surname>Diao</surname></string-name>, et&#160;al., &#8220;<article-title>Charlson Comorbidity Index Helps Predict the Risk of Mortality for Patients With Type 2 Diabetic Nephropathy</article-title>,&#8221; <source>Journal of Zhejiang University. Science. B</source><volume>15</volume>, no. <issue>1</issue> (<year>2014</year>): <fpage>58</fpage>&#8211;<lpage>66</lpage>, <pub-id pub-id-type="doi">10.1631/jzus.B1300109</pub-id>.<pub-id pub-id-type="pmid">24390745</pub-id><pub-id pub-id-type="pmcid">PMC3891119</pub-id></mixed-citation></ref><ref id="liv16132-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="liv16132-cit-0022"><string-name name-style="western"><given-names>Z.</given-names><surname>Rashid</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Munir</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Woldesenbet</surname></string-name>, et&#160;al., &#8220;<article-title>Association Between Social Determinants of Health and Delayed Postoperative Adjuvant Therapy Among Patients Undergoing Resection of Pancreatic Cancer</article-title>,&#8221; <source>Journal of Surgical Oncology</source><volume>129</volume>, no. <issue>5</issue> (<year>2024</year>): <fpage>850</fpage>&#8211;<lpage>859</lpage>, <pub-id pub-id-type="doi">10.1002/jso.27571</pub-id>.<pub-id pub-id-type="pmid">38151795</pub-id></mixed-citation></ref><ref id="liv16132-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="liv16132-cit-0023"><string-name name-style="western"><given-names>D. H.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Schneeweiss</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Glynn</surname></string-name>, <string-name name-style="western"><given-names>L. A.</given-names><surname>Lipsitz</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Rockwood</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Avorn</surname></string-name>, &#8220;<article-title>Measuring Frailty in Medicare Data: Development and Validation of a Claims&#8208;Based Frailty Index</article-title>,&#8221; <source>Journals of Gerontology. Series A, Biological Sciences and Medical Sciences</source><volume>73</volume>, no. <issue>7</issue> (<year>2018</year>): <fpage>980</fpage>&#8211;<lpage>987</lpage>, <pub-id pub-id-type="doi">10.1093/gerona/glx229</pub-id>.<pub-id pub-id-type="pmid">29244057</pub-id><pub-id pub-id-type="pmcid">PMC6001883</pub-id></mixed-citation></ref><ref id="liv16132-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="liv16132-cit-0024"><string-name name-style="western"><given-names>F.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>K. L.</given-names><surname>Morgan</surname></string-name>, and <string-name name-style="western"><given-names>A. M.</given-names><surname>Zaslavsky</surname></string-name>, &#8220;<article-title>Balancing Covariates via Propensity Score Weighting</article-title>,&#8221; <source>Journal of the American Statistical Association</source><volume>113</volume>, no. <issue>521</issue> (<year>2018</year>): <fpage>390</fpage>&#8211;<lpage>400</lpage>, <pub-id pub-id-type="doi">10.1080/01621459.2016.1260466</pub-id>.</mixed-citation></ref><ref id="liv16132-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="liv16132-cit-0025"><string-name name-style="western"><given-names>L. E.</given-names><surname>Thomas</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Li</surname></string-name>, and <string-name name-style="western"><given-names>M. J.</given-names><surname>Pencina</surname></string-name>, &#8220;<article-title>Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial</article-title>,&#8221; <source>Journal of the American Medical Association</source><volume>323</volume>, no. <issue>23</issue> (<year>2020</year>): <fpage>2417</fpage>&#8211;<lpage>2418</lpage>, <pub-id pub-id-type="doi">10.1001/jama.2020.7819</pub-id>.<pub-id pub-id-type="pmid">32369102</pub-id></mixed-citation></ref><ref id="liv16132-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="liv16132-cit-0026"><string-name name-style="western"><given-names>P. C.</given-names><surname>Austin</surname></string-name>, &#8220;<article-title>An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies</article-title>,&#8221; <source>Multivariate Behavioral Research</source><volume>46</volume>, no. <issue>3</issue> (<year>2011</year>): <fpage>399</fpage>&#8211;<lpage>424</lpage>, <pub-id pub-id-type="doi">10.1080/00273171.2011.568786</pub-id>.<pub-id pub-id-type="pmid">21818162</pub-id><pub-id pub-id-type="pmcid">PMC3144483</pub-id></mixed-citation></ref><ref id="liv16132-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="liv16132-cit-0027"><string-name name-style="western"><given-names>R.</given-names><surname>Simon</surname></string-name> and <string-name name-style="western"><given-names>R. W.</given-names><surname>Makuch</surname></string-name>, &#8220;<article-title>A Non&#8208;parametric Graphical Representation of the Relationship Between Survival and the Occurrence of an Event: Application to Responder Versus Non&#8208;Responder Bias</article-title>,&#8221; <source>Statistics in Medicine</source><volume>3</volume>, no. <issue>1</issue> (<year>1984</year>): <fpage>35</fpage>&#8211;<lpage>44</lpage>, <pub-id pub-id-type="doi">10.1002/sim.4780030106</pub-id>.<pub-id pub-id-type="pmid">6729287</pub-id></mixed-citation></ref><ref id="liv16132-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="liv16132-cit-0028"><string-name name-style="western"><given-names>D.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>A. A.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Gadiparthi</surname></string-name>, et&#160;al., &#8220;<article-title>Changing Trends in Etiology&#8208;Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016</article-title>,&#8221; <source>Gastroenterology</source><volume>155</volume>, no. <issue>4</issue> (<year>2018</year>): <fpage>1154</fpage>&#8211;<lpage>1163.e3</lpage>, <pub-id pub-id-type="doi">10.1053/j.gastro.2018.07.008</pub-id>.<pub-id pub-id-type="pmid">30009816</pub-id><pub-id pub-id-type="pmcid">PMC6467699</pub-id></mixed-citation></ref><ref id="liv16132-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="liv16132-cit-0029"><string-name name-style="western"><given-names>E.</given-names><surname>Stein</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Cruz&#8208;Lemini</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Altamirano</surname></string-name>, et&#160;al., &#8220;<article-title>Heavy Daily Alcohol Intake at the Population Level Predicts the Weight of Alcohol in Cirrhosis Burden Worldwide</article-title>,&#8221; <source>Journal of Hepatology</source><volume>65</volume>, no. <issue>5</issue> (<year>2016</year>): <fpage>998</fpage>&#8211;<lpage>1005</lpage>, <pub-id pub-id-type="doi">10.1016/j.jhep.2016.06.018</pub-id>.<pub-id pub-id-type="pmid">27392424</pub-id></mixed-citation></ref><ref id="liv16132-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="liv16132-cit-0030"><string-name name-style="western"><given-names>R.</given-names><surname>Bataller</surname></string-name>, <string-name name-style="western"><given-names>G. E.</given-names><surname>Arteel</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Moreno</surname></string-name>, and <string-name name-style="western"><given-names>V.</given-names><surname>Shah</surname></string-name>, &#8220;<article-title>Alcohol&#8208;Related Liver Disease: Time for Action</article-title>,&#8221; <source>Journal of Hepatology</source><volume>70</volume>, no. <issue>2</issue> (<year>2019</year>): <fpage>221</fpage>&#8211;<lpage>222</lpage>, <pub-id pub-id-type="doi">10.1016/j.jhep.2018.12.007</pub-id>.<pub-id pub-id-type="pmid">30658723</pub-id><pub-id pub-id-type="pmcid">PMC6416779</pub-id></mixed-citation></ref><ref id="liv16132-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="liv16132-cit-0031"><string-name name-style="western"><given-names>G.</given-names><surname>Ayares</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Idalsoaga</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Arnold</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Fuentes&#8208;L&#243;pez</surname></string-name>, <string-name name-style="western"><given-names>J. P.</given-names><surname>Arab</surname></string-name>, and <string-name name-style="western"><given-names>L. A.</given-names><surname>D&#237;az</surname></string-name>, &#8220;<article-title>Public Health Measures and Prevention of Alcohol&#8208;Associated Liver Disease</article-title>,&#8221; <source>Journal of Clinical and Experimental Hepatology</source><volume>12</volume>, no. <issue>6</issue> (<year>2022</year>): <fpage>1480</fpage>&#8211;<lpage>1491</lpage>, <pub-id pub-id-type="doi">10.1016/j.jceh.2022.05.005</pub-id>.<pub-id pub-id-type="pmid">36340308</pub-id><pub-id pub-id-type="pmcid">PMC9630023</pub-id></mixed-citation></ref><ref id="liv16132-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="liv16132-cit-0032"><string-name name-style="western"><given-names>H. R.</given-names><surname>Kranzler</surname></string-name> and <string-name name-style="western"><given-names>M.</given-names><surname>Soyka</surname></string-name>, &#8220;<article-title>Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review</article-title>,&#8221; <source>Journal of the American Medical Association</source><volume>320</volume>, no. <issue>8</issue> (<year>2018</year>): <fpage>815</fpage>&#8211;<lpage>824</lpage>, <pub-id pub-id-type="doi">10.1001/jama.2018.11406</pub-id>.<pub-id pub-id-type="pmid">30167705</pub-id><pub-id pub-id-type="pmcid">PMC7391072</pub-id></mixed-citation></ref><ref id="liv16132-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="liv16132-cit-0033"><string-name name-style="western"><given-names>Y.</given-names><surname>Chang</surname></string-name>, <string-name name-style="western"><given-names>Y. K.</given-names><surname>Cho</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Cho</surname></string-name>, et&#160;al., &#8220;<article-title>Alcoholic and Nonalcoholic Fatty Liver Disease and Liver&#8208;Related Mortality: A Cohort Study</article-title>,&#8221; <source>Official Journal of the American College of Gastroenterology|ACG</source><volume>114</volume>, no. <issue>4</issue> (<year>2019</year>): <fpage>620</fpage>, <pub-id pub-id-type="doi">10.14309/ajg.0000000000000074</pub-id>.<pub-id pub-id-type="pmid">30694866</pub-id></mixed-citation></ref><ref id="liv16132-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="liv16132-cit-0034"><string-name name-style="western"><given-names>J.</given-names><surname>Omar J&#225;quez Quintana</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Garc&#237;a&#8208;Compean</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Alberto Gonz&#225;lez Gonz&#225;lez</surname></string-name>, et&#160;al., &#8220;<article-title>The Impact of Diabetes Mellitus in Mortality of Patients With Compensated Liver Cirrhosis&#8212;A Prospective Study</article-title>,&#8221; <source>Annals of Hepatology</source><volume>10</volume>, no. <issue>1</issue> (<year>2011</year>): <fpage>56</fpage>&#8211;<lpage>62</lpage>, <pub-id pub-id-type="doi">10.1016/S1665-2681(19)31588-1</pub-id>.<pub-id pub-id-type="pmid">21301011</pub-id></mixed-citation></ref><ref id="liv16132-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="liv16132-cit-0035"><string-name name-style="western"><given-names>F. S.</given-names><surname>Yen</surname></string-name>, <string-name name-style="western"><given-names>C. C.</given-names><surname>Hsu</surname></string-name>, <string-name name-style="western"><given-names>J. C. C.</given-names><surname>Wei</surname></string-name>, <string-name name-style="western"><given-names>M. C.</given-names><surname>Hou</surname></string-name>, and <string-name name-style="western"><given-names>C. M.</given-names><surname>Hwu</surname></string-name>, &#8220;<article-title>Selection and Warning of Evidence&#8208;Based Antidiabetic Medications for Patients With Chronic Liver Disease</article-title>,&#8221; <source>Frontiers in Medicine</source><volume>9</volume> (<year>2022</year>): <fpage>9</fpage>, <pub-id pub-id-type="doi">10.3389/fmed.2022.839456</pub-id>.<pub-id pub-id-type="pmcid">PMC8888965</pub-id><pub-id pub-id-type="pmid">35252271</pub-id></mixed-citation></ref><ref id="liv16132-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="liv16132-cit-0036"><string-name name-style="western"><given-names>P. N.</given-names><surname>Newsome</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Kristine</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Kenneth</surname></string-name>, et&#160;al., &#8220;<article-title>A Placebo&#8208;Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>384</volume>, no. <issue>12</issue> (<year>2021</year>): <fpage>1113</fpage>&#8211;<lpage>1124</lpage>, <pub-id pub-id-type="doi">10.1056/NEJMoa2028395</pub-id>.<pub-id pub-id-type="pmid">33185364</pub-id></mixed-citation></ref><ref id="liv16132-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="liv16132-cit-0037"><string-name name-style="western"><given-names>D. J.</given-names><surname>Cuthbertson</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Irwin</surname></string-name>, <string-name name-style="western"><given-names>C. J.</given-names><surname>Gardner</surname></string-name>, et&#160;al., &#8220;<article-title>Improved Glycaemia Correlates With Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon&#8208;Like Peptide&#8208;1 (GLP&#8208;1) Receptor Agonists</article-title>,&#8221; <source>PLoS One</source><volume>7</volume>, no. <issue>12</issue> (<year>2012</year>): <elocation-id>e50117</elocation-id>, <pub-id pub-id-type="doi">10.1371/journal.pone.0050117</pub-id>.<pub-id pub-id-type="pmid">23236362</pub-id><pub-id pub-id-type="pmcid">PMC3516516</pub-id></mixed-citation></ref><ref id="liv16132-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="liv16132-cit-0038"><string-name name-style="western"><given-names>L.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>N. A.</given-names><surname>Berger</surname></string-name>, <string-name name-style="western"><given-names>D. C.</given-names><surname>Kaelber</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Xu</surname></string-name>, &#8220;<article-title>Association of GLP&#8208;1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes</article-title>,&#8221; <source>Gastroenterology</source><volume>167</volume>, no. <issue>4</issue> (<year>2024</year>): <fpage>689</fpage>&#8211;<lpage>703</lpage>, <pub-id pub-id-type="doi">10.1053/j.gastro.2024.04.029</pub-id>.<pub-id pub-id-type="pmid">38692395</pub-id></mixed-citation></ref><ref id="liv16132-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="liv16132-cit-0039"><string-name name-style="western"><given-names>A. J.</given-names><surname>Scheen</surname></string-name>, &#8220;<article-title>Pharmacokinetic and Toxicological Considerations for the Treatment of Diabetes in Patients With Liver Disease</article-title>,&#8221; <source>Expert Opinion on Drug Metabolism &amp; Toxicology</source><volume>10</volume>, no. <issue>6</issue> (<year>2014</year>): <fpage>839</fpage>&#8211;<lpage>857</lpage>, <pub-id pub-id-type="doi">10.1517/17425255.2014.902444</pub-id>.<pub-id pub-id-type="pmid">24669954</pub-id></mixed-citation></ref><ref id="liv16132-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="liv16132-cit-0040"><string-name name-style="western"><given-names>C.</given-names><surname>Pyke</surname></string-name>, <string-name name-style="western"><given-names>R. S.</given-names><surname>Heller</surname></string-name>, <string-name name-style="western"><given-names>R. K.</given-names><surname>Kirk</surname></string-name>, et&#160;al., &#8220;<article-title>GLP&#8208;1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody</article-title>,&#8221; <source>Endocrinology</source><volume>155</volume>, no. <issue>4</issue> (<year>2014</year>): <fpage>1280</fpage>&#8211;<lpage>1290</lpage>, <pub-id pub-id-type="doi">10.1210/en.2013-1934</pub-id>.<pub-id pub-id-type="pmid">24467746</pub-id></mixed-citation></ref><ref id="liv16132-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="liv16132-cit-0041"><string-name name-style="western"><given-names>P.</given-names><surname>Gin&#232;s</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Sol&#224;</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Angeli</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Wong</surname></string-name>, <string-name name-style="western"><given-names>M. K.</given-names><surname>Nadim</surname></string-name>, and <string-name name-style="western"><given-names>P. S.</given-names><surname>Kamath</surname></string-name>, &#8220;<article-title>Hepatorenal Syndrome</article-title>,&#8221; <source>Nature Reviews. Disease Primers</source><volume>4</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>23</fpage>, <pub-id pub-id-type="doi">10.1038/s41572-018-0022-7</pub-id>.<pub-id pub-id-type="pmid">30213943</pub-id></mixed-citation></ref><ref id="liv16132-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="liv16132-cit-0042"><string-name name-style="western"><given-names>M. C.</given-names><surname>Honigberg</surname></string-name>, <string-name name-style="western"><given-names>L. S.</given-names><surname>Chang</surname></string-name>, <string-name name-style="western"><given-names>D. K.</given-names><surname>McGuire</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Plutzky</surname></string-name>, <string-name name-style="western"><given-names>V. R.</given-names><surname>Aroda</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Vaduganathan</surname></string-name>, &#8220;<article-title>Use of Glucagon&#8208;Like Peptide&#8208;1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review</article-title>,&#8221; <source>Journal of the American Medical Association Cardiology</source><volume>5</volume>, no. <issue>10</issue> (<year>2020</year>): <fpage>1182</fpage>&#8211;<lpage>1190</lpage>, <pub-id pub-id-type="doi">10.1001/jamacardio.2020.1966</pub-id>.<pub-id pub-id-type="pmid">32584928</pub-id><pub-id pub-id-type="pmcid">PMC7744318</pub-id></mixed-citation></ref><ref id="liv16132-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="liv16132-cit-0043"><string-name name-style="western"><given-names>D. O.</given-names><surname>Ogunsanmi</surname></string-name>, <string-name name-style="western"><given-names>A. T.</given-names><surname>Harrison</surname></string-name>, <string-name name-style="western"><given-names>A. R.</given-names><surname>Pakker</surname></string-name>, <string-name name-style="western"><given-names>C. P.</given-names><surname>Kovesdy</surname></string-name>, <string-name name-style="western"><given-names>J. E.</given-names><surname>Bailey</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Surbhi</surname></string-name>, &#8220;<article-title>Comorbidities and Neighborhood Factors Associated With Prescription of Sodium&#8208;Glucose Cotransporter Protein&#8208;2 Inhibitors and Glucagon&#8208;Like Peptide&#8208;1 Receptor Agonists Among Medically Underserved Populations</article-title>,&#8221; <source>Journal of Managed Care &amp; Specialty Pharmacy</source><volume>29</volume>, no. <issue>6</issue> (<year>2023</year>): <fpage>699</fpage>&#8211;<lpage>711</lpage>, <pub-id pub-id-type="doi">10.18553/jmcp.2023.29.6.699</pub-id>.<pub-id pub-id-type="pmid">37276038</pub-id><pub-id pub-id-type="pmcid">PMC10387916</pub-id></mixed-citation></ref><ref id="liv16132-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="liv16132-cit-0044"><string-name name-style="western"><given-names>N. S.</given-names><surname>Maitra</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Mahtta</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Navaneethan</surname></string-name>, et&#160;al., &#8220;<article-title>A Mistake Not to be Repeated: What Can we Learn From the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents?</article-title>,&#8221; <source>Current Cardiology Reports</source><volume>24</volume>, no. <issue>6</issue> (<year>2022</year>): <fpage>689</fpage>&#8211;<lpage>698</lpage>, <pub-id pub-id-type="doi">10.1007/s11886-022-01694-5</pub-id>.<pub-id pub-id-type="pmid">35352278</pub-id></mixed-citation></ref><ref id="liv16132-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="liv16132-cit-0045"><string-name name-style="western"><given-names>A. J.</given-names><surname>Scheen</surname></string-name>, &#8220;<article-title>Underuse of Glucose&#8208;Lowering Medications Associated With Cardiorenal Protection in Type 2 Diabetes: From Delayed Initiation to Untimely Discontinuation</article-title>,&#8221; <source>Lancet Regional Health &#8211; Europe</source><volume>29</volume> (<year>2023</year>): <fpage>29</fpage>, <pub-id pub-id-type="doi">10.1016/j.lanepe.2023.100627</pub-id>.<pub-id pub-id-type="pmcid">PMC10070122</pub-id><pub-id pub-id-type="pmid">37025106</pub-id></mixed-citation></ref><ref id="liv16132-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="liv16132-cit-0046"><string-name name-style="western"><given-names>A.</given-names><surname>Sumarsono</surname></string-name>, <string-name name-style="western"><given-names>B. M.</given-names><surname>Everett</surname></string-name>, <string-name name-style="western"><given-names>D. K.</given-names><surname>McGuire</surname></string-name>, et&#160;al., &#8220;<article-title>Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017</article-title>,&#8221; <source>Journal of the American Medical Association Internal Medicine</source><volume>180</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>141</fpage>&#8211;<lpage>144</lpage>, <pub-id pub-id-type="doi">10.1001/jamainternmed.2019.3884</pub-id>.<pub-id pub-id-type="pmid">31566649</pub-id><pub-id pub-id-type="pmcid">PMC6777260</pub-id></mixed-citation></ref><ref id="liv16132-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="liv16132-cit-0047"><string-name name-style="western"><given-names>J. A.</given-names><surname>de Souza</surname></string-name>, <string-name name-style="western"><given-names>B. J.</given-names><surname>Yap</surname></string-name>, <string-name name-style="western"><given-names>F. J.</given-names><surname>Hlubocky</surname></string-name>, et&#160;al., &#8220;<article-title>The Development of a Financial Toxicity Patient&#8208;Reported Outcome in Cancer: The COST Measure</article-title>,&#8221; <source>Cancer</source><volume>120</volume>, no. <issue>20</issue> (<year>2014</year>): <fpage>3245</fpage>&#8211;<lpage>3253</lpage>, <pub-id pub-id-type="doi">10.1002/cncr.28814</pub-id>.<pub-id pub-id-type="pmid">24954526</pub-id></mixed-citation></ref><ref id="liv16132-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="liv16132-cit-0048"><string-name name-style="western"><given-names>Z.</given-names><surname>Rashid</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Munir</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Woldesenbet</surname></string-name>, et&#160;al., &#8220;<article-title>Association of Preoperative Cholangitis With Outcomes and Expenditures Among Patients Undergoing Pancreaticoduodenectomy</article-title>,&#8221; <source>Journal of Gastrointestinal Surgery</source><volume>28</volume>, no. <issue>7</issue> (<year>2024</year>): <fpage>1137</fpage>&#8211;<lpage>1144</lpage>, <pub-id pub-id-type="doi">10.1016/j.gassur.2024.05.009</pub-id>.<pub-id pub-id-type="pmid">38762337</pub-id></mixed-citation></ref><ref id="liv16132-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="liv16132-cit-0049"><string-name name-style="western"><given-names>Z.</given-names><surname>Rashid</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Munir</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Woldesenbet</surname></string-name>, et&#160;al., &#8220;<article-title>Care Fragmentation in Hepatopancreatic Surgery and Postoperative Outcomes</article-title>,&#8221; <source>Surgery</source><volume>175</volume>, no. <issue>6</issue> (<year>2024</year>): <fpage>1562</fpage>&#8211;<lpage>1569</lpage>, <pub-id pub-id-type="doi">10.1016/j.surg.2024.02.021</pub-id>.<pub-id pub-id-type="pmid">38565495</pub-id></mixed-citation></ref><ref id="liv16132-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="liv16132-cit-0050"><string-name name-style="western"><given-names>M. E.</given-names><surname>Malik</surname></string-name>, <string-name name-style="western"><given-names>A. C.</given-names><surname>Falkentoft</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Jensen</surname></string-name>, et&#160;al., &#8220;<article-title>Discontinuation and Reinitiation of SGLT&#8208;2 Inhibitors and GLP&#8208;1R Agonists in Patients With Type 2 Diabetes: A Nationwide Study From 2013 to 2021</article-title>,&#8221; <source>Lancet Regional Health &#8211; Europe</source><volume>29</volume> (<year>2023</year>): <fpage>29</fpage>, <pub-id pub-id-type="doi">10.1016/j.lanepe.2023.100617</pub-id>.<pub-id pub-id-type="pmcid">PMC10230617</pub-id><pub-id pub-id-type="pmid">37265783</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>